Inhibition	O
of	O
STAT3	O
signaling	O
leads	O
to	O
apoptosis	O
of	O
leukemic	B-cell_type
large	I-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
and	O
decreased	O
Mcl-1	O
expression	O
.	O

Large	O
granular	O
lymphocyte	O
(	O
LGL	O
)	O
leukemia	O
is	O
characterized	O
by	O
the	O
expansion	O
of	O
antigen-activated	B-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

These	O
leukemic	B-cell_type
cells	I-cell_type
are	O
resistant	O
to	O
Fas-mediated	O
apoptosis	O
despite	O
expressing	O
high	O
levels	O
of	O
Fas	B-protein
.	O

We	O
found	O
that	O
leukemic	B-cell_type
LGL	I-cell_type
from	O
19	O
patients	O
displayed	O
high	O
levels	O
of	O
activated	B-protein
STAT3	I-protein
.	O

Treatment	O
of	O
leukemic	B-cell_type
LGL	I-cell_type
with	O
the	O
JAK-selective	O
tyrosine	O
kinase	O
inhibitor	O
AG-490	O
induced	O
apoptosis	O
with	O
a	O
corresponding	O
decrease	O
in	O
STAT	B-protein
-DNA	O
binding	O
activity	O
.	O

Moreover	O
,	O
using	O
an	O
antisense	O
oligonucleotide	O
approach	O
to	O
diminish	O
STAT3	O
expression	O
,	O
we	O
found	O
that	O
Fas	O
sensitivity	O
was	O
restored	O
in	O
leukemic	B-cell_type
LGL	I-cell_type
.	O

AG-490-induced	O
apoptosis	O
in	O
leukemic	B-cell_type
LGL	I-cell_type
was	O
independent	O
of	O
Bcl-xL	O
or	O
Bcl-2	O
expression	O
.	O

However	O
,	O
we	O
found	O
that	O
the	O
Bcl-2-family	B-protein
protein	I-protein
Mcl-1	I-protein
was	O
significantly	O
reduced	O
by	O
AG-490	O
treatment	O
.	O

Activated	B-protein
STAT3	I-protein
was	O
shown	O
to	O
bind	O
an	O
SIE-related	B-DNA
element	I-DNA
in	O
the	O
murine	B-DNA
mcl-1	I-DNA
promoter	I-DNA
.	O

Using	O
a	O
luciferase	O
reporter	O
assay	O
,	O
we	O
demonstrated	O
that	O
v-src	O
overexpression	O
in	O
NIH3T3	O
induced	O
STAT3	B-protein
-dependent	O
transcriptional	O
activity	O
from	O
the	O
mcl-1	B-DNA
promoter	I-DNA
and	O
increased	O
endogenous	O
Mcl-1	O
protein	O
levels	O
.	O

We	O
conclude	O
that	O
STAT3	B-protein
activation	O
contributed	O
to	O
accumulation	O
of	O
the	O
leukemic	B-cell_type
LGL	I-cell_type
clones	I-cell_type
.	O

These	O
findings	O
suggest	O
that	O
investigation	O
should	O
focus	O
on	O
novel	O
strategies	O
targeting	O
STAT3	B-protein
in	O
the	O
treatment	O
of	O
LGL	O
leukemia	O
.	O

Inhibition	NULL
of	NULL
STAT	NULL
3	NULL
signaling	NULL
leads	NULL
to	NULL
apoptosis	NULL
of	NULL
leukemic	NULL
large	NULL
granular	NULL
lymphocytes	NULL
and	NULL
decreased	NULL
Mcl-1	NULL
expression	NULL
P.K	NULL
.	NULL

Epling-Burnette	NULL
,	NULL
``	NULL
Jin	NULL
Hong	NULL
Liu	NULL
,	NULL
Robyn	NULL
Catlett-Falcone	NULL
,	NULL
**	NULL
James	NULL
Turkson,4	NULL
``	NULL
Marc	NULL
Oshiro	NULL
,	NULL
°	NULL
Ravi	NULL
Kothapalli	NULL
,	NULL
Yongxiang	NULL
Li	NULL
,	NULL
Ju-Ming	NULL
Wang	NULL
,	NULL
``	NULL
Hsin-Fang	NULL
Yang-Yen	NULL
,	NULL
``	NULL
James	NULL
Karras,8	NULL
Richard	NULL
Jove	NULL
,	NULL
*	NULL
``	NULL
and	NULL
Thomas	NULL
P.	NULL
Loughran	NULL
,	NULL
Jr.	NULL
``	NULL
``	NULL
'Hematologic	NULL
Malignancy	NULL
Program	NULL
,	NULL
H.	NULL
Lee	NULL
Moffitt	NULL
Cancer	NULL
Center	NULL
and	NULL
Research	NULL
Institute	NULL
,	NULL
*Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
Veterans	NULL
Administration	NULL
Hospital	NULL
,	NULL
*Molecular	NULL
Oncology	NULL
Program	NULL
,	NULL
H.	NULL
Lee	NULL
Moffitt	NULL
Cancer	NULL
Center	NULL
and	NULL
Research	NULL
Institute	NULL
,	NULL
$	NULL
Department	NULL
of	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
and	NULL
SClinical	NULL
Investigations	NULL
Program	NULL
,	NULL
H.	NULL
Lee	NULL
Moffitt	NULL
Cancer	NULL
Center	NULL
and	NULL
Research	NULL
Institute	NULL
,	NULL
University	NULL
of	NULL
South	NULL
Florida	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Tampa	NULL
,	NULL
Florida	NULL
,	NULL
USA	NULL
``	NULL
Institute	NULL
of	NULL
Molecular	NULL
Biology	NULL
,	NULL
National	NULL
Taiwan	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Taipei	NULL
,	NULL
Taiwan	NULL
*Department	NULL
of	NULL
Molecular	NULL
Pharmacology	NULL
,	NULL
Isis	NULL
Pharmaceuticals	NULL
Inc.	NULL
,	NULL
Carlsbad	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
*Department	NULL
of	NULL
Immunology	NULL
and	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
South	NULL
Florida	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Tampa	NULL
,	NULL
Florida	NULL
,	NULL
USA	NULL
Address	NULL
correspondence	NULL
to	NULL
:	NULL
P.K	NULL
.	NULL

Epling-Burnette	NULL
,	NULL
Hematologic	NULL
Malignancy	NULL
Program	NULL
,	NULL
12902	NULL
Magnolia	NULL
Drive	NULL
,	NULL
MRC	NULL
,	NULL
Room	NULL
2068	NULL
f	NULL
and	NULL
g	NULL
,	NULL
Tampa	NULL
,	NULL
Florida	NULL
33612	NULL
,	NULL
USA	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
813	NULL
)	NULL
972-8454	NULL
;	NULL
Fax	NULL
:	NULL
(	NULL
813	NULL
)	NULL
972-6700	NULL
;	NULL
E-mail	NULL
:	NULL
burnetpk	NULL
@	NULL
moffitt.usf.edu	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
March	NULL
22	NULL
,	NULL
2000	NULL
,	NULL
and	NULL
accepted	NULL
in	NULL
revised	NULL
form	NULL
December	NULL
12	NULL
,	NULL
2000	NULL
.	NULL

Large	NULL
granular	NULL
lymphocyte	NULL
(	NULL
LGL	NULL
)	NULL
leukemia	NULL
is	NULL
characterized	NULL
by	NULL
the	NULL
expansion	NULL
of	NULL
antigen-activated	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

These	NULL
leukemic	NULL
cells	NULL
are	NULL
resistant	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
despite	NULL
expressing	NULL
high	NULL
levels	NULL
of	NULL
Fas	NULL
.	NULL

We	NULL
found	NULL
that	NULL
leukemic	NULL
LGL	NULL
from	NULL
19	NULL
patients	NULL
displayed	NULL
high	NULL
levels	NULL
of	NULL
activated	NULL
STAT3	NULL
.	NULL

Treatment	NULL
of	NULL
leukemic	NULL
LGL	NULL
with	NULL
the	NULL
JAK-selective	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
AG-490	NULL
induced	NULL
apoptosis	NULL
with	NULL
a	NULL
corresponding	NULL
decrease	NULL
in	NULL
STAT-DNA	NULL
binding	NULL
activity	NULL
.	NULL

More-over	NULL
,	NULL
using	NULL
an	NULL
antisense	NULL
oligonucleotide	NULL
approach	NULL
to	NULL
diminish	NULL
STAT	NULL
3	NULL
expression	NULL
,	NULL
we	NULL
found	NULL
that	NULL
Fas	NULL
sensitivity	NULL
was	NULL
restored	NULL
in	NULL
leukemic	NULL
LGL	NULL
.	NULL

AG-490-induced	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGL	NULL
was	NULL
independent	NULL
of	NULL
Bel-x	NULL
;	NULL
,	NULL
or	NULL
Bel-2	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
Bel-2-family	NULL
protein	NULL
Mcl-1	NULL
was	NULL
significantly	NULL
reduced	NULL
by	NULL
AG-490	NULL
treatment	NULL
.	NULL

Activated	NULL
STAT	NULL
3	NULL
was	NULL
shown	NULL
to	NULL
bind	NULL
an	NULL
SIE-related	NULL
element	NULL
in	NULL
the	NULL
murine	NULL
mel-1	NULL
promoter	NULL
.	NULL

Using	NULL
a	NULL
luciferase	NULL
reporter	NULL
assay	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
v-src	NULL
overexpression	NULL
in	NULL
NIH3T3	NULL
induced	NULL
STAT	NULL
transcriptional	NULL
activity	NULL
from	NULL
the	NULL
mel-1	NULL
promoter	NULL
and	NULL
increased	NULL
endogenous	NULL
Mcl-1	NULL
protein	NULL
levels	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
STAT3	NULL
activation	NULL
contributed	NULL
to	NULL
accumulation	NULL
of	NULL
the	NULL
leukemic	NULL
LGL	NULL
clones	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
investigation	NULL
should	NULL
focus	NULL
on	NULL
novel	NULL
strategies	NULL
targeting	NULL
STAT3	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
LGL	NULL
leukemia	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

107:351-362	NULL
(	NULL
2001	NULL
)	NULL
.	NULL

Introduction	NULL
Large	NULL
granular	NULL
lymphocyte	NULL
(	NULL
LGL	NULL
)	NULL
leukemia	NULL
(	NULL
CD3	NULL
)	NULL
is	NULL
a	NULL
clonal	NULL
T-cell	NULL
lymphoproliferative	NULL
disease	NULL
with	NULL
autoimmune	NULL
features	NULL
and	NULL
chronic	NULL
neutropenia	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
disease	NULL
is	NULL
characterized	NULL
by	NULL
the	NULL
expansion	NULL
of	NULL
CD3	NULL
#	NULL
,	NULL
CD8*	NULL
,	NULL
CD57	NULL
LGLs	NULL
,	NULL
with	NULL
many	NULL
similarities	NULL
to	NULL
antigen-activated	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTLs	NULL
)	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
characteristic	NULL
of	NULL
CTLs	NULL
,	NULL
the	NULL
leukemic	NULL
cells	NULL
constitutively	NULL
express	NULL
perforin	NULL
and	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
)	NULL
(	NULL
3	NULL
)	NULL
.	NULL

After	NULL
repeated	NULL
anti-genic	NULL
stimulation	NULL
,	NULL
normal	NULL
CTL	NULL
are	NULL
targeted	NULL
for	NULL
cell	NULL
death	NULL
through	NULL
the	NULL
Fas/FasL	NULL
apoptotic	NULL
pathway	NULL
(	NULL
FasR	NULL
,	NULL
CD95	NULL
)	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Animal	NULL
models	NULL
of	NULL
lymphoproliferative	NULL
disorders	NULL
with	NULL
autoimmune	NULL
features	NULL
such	NULL
as	NULL
Ipr/lpr	NULL
and	NULL
gid	NULL
/gld	NULL
mice	NULL
are	NULL
characterized	NULL
by	NULL
insensitivity	NULL
to	NULL
Fas-dependent	NULL
cell	NULL
death	NULL
due	NULL
to	NULL
mutations	NULL
in	NULL
the	NULL
FasR	NULL
or	NULL
FasL	NULL
,	NULL
respectively	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Our	NULL
laboratory	NULL
has	NULL
shown	NULL
that	NULL
leukemic	NULL
LGL	NULL
are	NULL
resistant	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
despite	NULL
high	NULL
levels	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
expression	NULL
(	NULL
8	NULL
)	NULL
.	NULL

No	NULL
mutations	NULL
in	NULL
Fas	NULL
were	NULL
found	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

Treatment	NULL
of	NULL
leukemic	NULL
LGLs	NULL
with	NULL
PHA	NULL
+	NULL
IL-2	NULL
or	NULL
with	NULL
ceramide	NULL
reversed	NULL
Fas	NULL
resistance	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
FasR	NULL
and	NULL
apoptotic	NULL
machinery	NULL
are	NULL
intact	NULL
.	NULL

The	NULL
myeloma	NULL
cell	NULL
line	NULL
,	NULL
U266	NULL
,	NULL
is	NULL
also	NULL
resistant	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
despite	NULL
expressing	NULL
high	NULL
levels	NULL
of	NULL
Fas	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Recent	NULL
data	NULL
indicate	NULL
that	NULL
constitutive	NULL
activation	NULL
of	NULL
STAT3	NULL
signaling	NULL
leads	NULL
to	NULL
apoptotic	NULL
resistance	NULL
in	NULL
U266	NULL
cells	NULL
.	NULL

STAT	NULL
family	NULL
proteins	NULL
are	NULL
latent	NULL
cytoplasmic	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
sequence-specific	NULL
transcriptional	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
target	NULL
genes	NULL
(	NULL
10-12	NULL
)	NULL
.	NULL

They	NULL
are	NULL
regulated	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
which	NULL
leads	NULL
to	NULL
homodimer-ization	NULL
or	NULL
heterodimerization	NULL
with	NULL
other	NULL
STAT	NULL
proteins	NULL
and	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

The	NULL
Janus	NULL
(	NULL
JAK	NULL
)	NULL
family	NULL
of	NULL
tyrosine	NULL
kinases	NULL
that	NULL
include	NULL
The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume107	NULL
|	NULL
Number3	NULL
351	NULL
352	NULL
JAK1	NULL
,	NULL
JAK2	NULL
,	NULL
JAK3	NULL
,	NULL
and	NULL
TYK2	NULL
mediates	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT	NULL
proteins	NULL
(	NULL
15-17	NULL
)	NULL
.	NULL

STAT	NULL
activation	NULL
is	NULL
also	NULL
induced	NULL
by	NULL
diverse	NULL
oncoproteins	NULL
including	NULL
v-sre	NULL
,	NULL
v-abl	NULL
,	NULL
v-fps	NULL
,	NULL
v-fes	NULL
,	NULL
and	NULL
v-eyk	NULL
(	NULL
18-22	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
many	NULL
types	NULL
of	NULL
human	NULL
tumors	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
express	NULL
constitutively	NULL
activated	NULL
STAT3	NULL
,	NULL
STATS	NULL
,	NULL
or	NULL
STAT1	NULL
proteins	NULL
(	NULL
23-27	NULL
)	NULL
.	NULL

The	NULL
v-src	NULL
transformation	NULL
of	NULL
NIH3T3	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
STAT3-dominant	NULL
interfering	NULL
protein	NULL
(	NULL
STAT	NULL
3B	NULL
)	NULL
that	NULL
blocks	NULL
transcription	NULL
but	NULL
not	NULL
dimerization	NULL
,	NULL
yielding	NULL
direct	NULL
evidence	NULL
of	NULL
STAT3	NULL
involvement	NULL
in	NULL
cellular	NULL
transformation	NULL
(	NULL
28-30	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
first	NULL
assessed	NULL
whether	NULL
leukemic	NULL
LGLs	NULL
harbor	NULL
activated	NULL
STAT	NULL
proteins	NULL
.	NULL

We	NULL
discovered	NULL
that	NULL
STAT3	NULL
and/or	NULL
STAT1	NULL
were	NULL
constitutively	NULL
activated	NULL
in	NULL
leukemic	NULL
LGL	NULL
.	NULL

To	NULL
elucidate	NULL
the	NULL
role	NULL
of	NULL
activated	NULL
STAT	NULL
1	NULL
and	NULL
STAT	NULL
3	NULL
proteins	NULL
in	NULL
the	NULL
survival	NULL
of	NULL
leukemic	NULL
LGL	NULL
,	NULL
we	NULL
treated	NULL
the	NULL
patients	NULL
'	NULL
PBMCs	NULL
in	NULL
vitro	NULL
with	NULL
AG-490	NULL
,	NULL
a	NULL
selective	NULL
inhibitor	NULL
of	NULL
JAK-family	NULL
kinases	NULL
.	NULL

We	NULL
also	NULL
utilized	NULL
STAT3	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
inhibit	NULL
STAT3	NULL
expression	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
inhibition	NULL
of	NULL
the	NULL
JAK/STAT	NULL
pathway	NULL
resulted	NULL
in	NULL
apoptosis	NULL
of	NULL
CD8+	NULL
leukemic	NULL
cells	NULL
and	NULL
reversal	NULL
of	NULL
Fas	NULL
resistance	NULL
in	NULL
some	NULL
leukemic	NULL
cells	NULL
.	NULL

STAT3	NULL
transcriptional	NULL
activation	NULL
of	NULL
an	NULL
antiapoptotic	NULL
protein	NULL
,	NULL
Bcl-x	NULL
,	NULL
controlled	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
and	NULL
chemotherapeutic	NULL
drug	NULL
resistance	NULL
in	NULL
U266	NULL
cells	NULL
(	NULL
9	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
we	NULL
found	NULL
that	NULL
induction	NULL
of	NULL
apoptosis	NULL
was	NULL
independent	NULL
of	NULL
Bcl-x	NULL
;	NULL
regulation	NULL
in	NULL
LGL	NULL
leukemia	NULL
.	NULL

Instead	NULL
,	NULL
AG-490	NULL
treatment	NULL
resulted	NULL
in	NULL
reduced	NULL
protein	NULL
expression	NULL
of	NULL
another	NULL
Bel-2-family	NULL
protein	NULL
,	NULL
Mcl-1	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
further	NULL
establish	NULL
that	NULL
mcl-1	NULL
,	NULL
like	NULL
Bel-x	NULL
;	NULL
,	NULL
is	NULL
also	NULL
a	NULL
STAT	NULL
3-regulated	NULL
gene	NULL
.	NULL

Methods	NULL
Patients	NULL
.	NULL

All	NULL
patients	NULL
met	NULL
the	NULL
clinical	NULL
criteria	NULL
of	NULL
T-cell	NULL
(	NULL
CD3+	NULL
)	NULL
LGL	NULL
leukemia	NULL
with	NULL
increased	NULL
LGL	NULL
counts	NULL
and	NULL
clonal	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
gene	NULL
rearrangements	NULL
.	NULL

Leukemic	NULL
LGL	NULL
from	NULL
all	NULL
but	NULL
two	NULL
patients	NULL
expressed	NULL
these	NULL
two	NULL
patients	NULL
(	NULL
10122	NULL
and	NULL
10110	NULL
)	NULL
displayed	NULL
TCR-y6	NULL
instead	NULL
.	NULL

All	NULL
patients	NULL
had	NULL
chronic	NULL
disease	NULL
not	NULL
requiring	NULL
treatment	NULL
at	NULL
the	NULL
time	NULL
of	NULL
analysis	NULL
.	NULL

Patient	NULL
numbers	NULL
were	NULL
assigned	NULL
after	NULL
accrual	NULL
into	NULL
the	NULL
national	NULL
LGL	NULL
leukemia	NULL
registry	NULL
initiated	NULL
at	NULL
the	NULL
H.	NULL
Lee	NULL
Moffitt	NULL
Cancer	NULL
Center	NULL
and	NULL
Research	NULL
Institute	NULL
(	NULL
www.moffitt.usf.edu/lgl-leukemia	NULL
)	NULL
.	NULL

Informed	NULL
consents	NULL
were	NULL
signed	NULL
by	NULL
all	NULL
patients	NULL
and	NULL
normal	NULL
individuals	NULL
to	NULL
allow	NULL
the	NULL
use	NULL
of	NULL
their	NULL
cells	NULL
for	NULL
these	NULL
experiments	NULL
(	NULL
IRB	NULL
no	NULL
.	NULL

4451	NULL
)	NULL
.	NULL

Cell	NULL
lysate	NULL
preparation	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
2	NULL
x	NULL
10	NULL
``	NULL
PBMCs	NULL
of	NULL
19	NULL
patients	NULL
with	NULL
LGL	NULL
leukemia	NULL
or	NULL
from	NULL
seven	NULL
normal	NULL
donors	NULL
,	NULL
as	NULL
well	NULL
as	NULL
from	NULL
U266	NULL
cells	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
,	NULL
19	NULL
)	NULL
.	NULL

PBMCs	NULL
were	NULL
separated	NULL
by	NULL
centrifugation	NULL
on	NULL
Ficoll-Hypaque	NULL
(	NULL
Amersham	NULL
Phar-macia	NULL
Biotech	NULL
,	NULL
Piscataway	NULL
,	NULL
New	NULL
Jersey	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Some	NULL
LGL	NULL
leukemia	NULL
cells	NULL
were	NULL
then	NULL
quickly	NULL
frozen	NULL
in	NULL
10	NULL
%	NULL
DMSO	NULL
containing	NULL
RPMI	NULL
and	NULL
placed	NULL
at	NULL
-70°C	NULL
before	NULL
extract	NULL
preparation	NULL
.	NULL

However	NULL
,	NULL
lysates	NULL
prepared	NULL
from	NULL
frozen	NULL
cells	NULL
of	NULL
three	NULL
patients	NULL
did	NULL
not	NULL
display	NULL
any	NULL
activated	NULL
STAT	NULL
proteins	NULL
.	NULL

Reanalysis	NULL
using	NULL
lysates	NULL
prepared	NULL
from	NULL
freshly	NULL
isolated	NULL
cells	NULL
in	NULL
these	NULL
patients	NULL
demonstrated	NULL
STAT	NULL
activation	NULL
.	NULL

The	NULL
loss	NULL
of	NULL
STAT	NULL
activity	NULL
with	NULL
freeze	NULL
thawing	NULL
of	NULL
cells	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
all	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
freshly	NULL
isolated	NULL
normal	NULL
and	NULL
patient	NULL
cells	NULL
.	NULL

Aliquots	NULL
of	NULL
the	NULL
extracts	NULL
were	NULL
stored	NULL
at	NULL
-80°C	NULL
and	NULL
used	NULL
only	NULL
once	NULL
after	NULL
thawing	NULL
to	NULL
prevent	NULL
protein	NULL
degradation	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
specific	NULL
STAT	NULL
family	NULL
members	NULL
,	NULL
blocking	NULL
or	NULL
supershifting	NULL
analyses	NULL
were	NULL
performed	NULL
.	NULL

For	NULL
both	NULL
STAT	NULL
3	NULL
and	NULL
STATS	NULL
supershift-ing	NULL
,	NULL
antibodies	NULL
were	NULL
used	NULL
.	NULL

In	NULL
such	NULL
experiments	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
STAT3	NULL
,	NULL
for	NULL
example	NULL
,	NULL
is	NULL
indicated	NULL
by	NULL
decreased	NULL
intensity	NULL
of	NULL
the	NULL
original	NULL
STAT3	NULL
complexes	NULL
and	NULL
by	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
new	NULL
higher	NULL
band	NULL
(	NULL
supershift	NULL
)	NULL
.	NULL

For	NULL
STAT	NULL
1	NULL
,	NULL
a	NULL
blocking	NULL
antibody	NULL
was	NULL
used	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
identification	NULL
of	NULL
STAT	NULL
1	NULL
is	NULL
shown	NULL
by	NULL
elimination	NULL
of	NULL
the	NULL
STAT	NULL
1	NULL
complex	NULL
.	NULL

For	NULL
these	NULL
experiments	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-STAT1	NULL
blocking	NULL
antibody	NULL
(	NULL
clone	NULL
C136	NULL
)	NULL
,	NULL
STAT3	NULL
supershifting	NULL
(	NULL
clone	NULL
H190	NULL
)	NULL
,	NULL
or	NULL
STAT5B	NULL
supershifting	NULL
antibody	NULL
(	NULL
clone	NULL
C17	NULL
)	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
incubation	NULL
reaction	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
a	NULL
10-LUl	NULL
reaction	NULL
vol-ume	NULL
.	NULL

Oligonucleotide	NULL
probes	NULL
(	NULL
2	NULL
pmol	NULL
)	NULL
containing	NULL
the	NULL
hSIE	NULL
sequence	NULL
Mcl-1	NULL
SIE	NULL
(	NULL
-103	NULL
to	NULL
-81	NULL
)	NULL
MGFe	NULL
sequence	NULL
(	NULL
5-AGATTTCTAGGAATTCAA-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
FIRE	NULL
GCGCT-3	NULL
``	NULL
)	NULL
(	NULL
all	NULL
from	NULL
Life	NULL
Technologies	NULL
Inc.	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Maryland	NULL
,	NULL
USA	NULL
)	NULL
were	NULL
labeled	NULL
with	NULL
P-dATP	NULL
and	NULL
dCTP	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
binding	NULL
was	NULL
determined	NULL
by	NULL
electrophoretic	NULL
analysis	NULL
on	NULL
a	NULL
5	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Drug	NULL
and	NULL
antisense	NULL
oligonucleotide	NULL
treatment	NULL
.	NULL

Purified	NULL
PBMCs	NULL
and	NULL
leukemic	NULL
LGLs	NULL
were	NULL
placed	NULL
in	NULL
24-well	NULL
plates	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2	NULL
x	NULL
106	NULL
per	NULL
0.5	NULL
ml	NULL
of	NULL
complete	NULL
medium	NULL
(	NULL
RPMI-1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
10	NULL
U/ml	NULL
penicillin	NULL
,	NULL
and	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
all	NULL
from	NULL
Life	NULL
Technologies	NULL
Inc.	NULL
)	NULL
.	NULL

The	NULL
U266	NULL
multiple	NULL
myeloma	NULL
cell	NULL
line	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
Maryland	NULL
,	NULL
USA	NULL
)	NULL
maintained	NULL
in	NULL
complete	NULL
medium	NULL
,	NULL
and	NULL
placed	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
x	NULL
105	NULL
cells	NULL
per	NULL
milliliter	NULL
in	NULL
24-well	NULL
plates	NULL
.	NULL

Normal	NULL
PBMCs	NULL
were	NULL
also	NULL
activated	NULL
with	NULL
1	NULL
ug/ml	NULL
of	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Missouri	NULL
,	NULL
USA	NULL
)	NULL
and	NULL
IL-2	NULL
(	NULL
500	NULL
U/ml	NULL
)	NULL
for	NULL
7-10	NULL
days	NULL
to	NULL
induce	NULL
Fas	NULL
sensitivity	NULL
(	NULL
8	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
displayed	NULL
CD25	NULL
in	NULL
98-100	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
by	NULL
FACS	NULL
analysis	NULL
at	NULL
the	NULL
time	NULL
of	NULL
apoptosis	NULL
analysis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
AG-490	NULL
at	NULL
the	NULL
indicated	NULL
concentration	NULL
or	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
drug	NULL
solvent	NULL
(	NULL
vehicle	NULL
con-trol	NULL
)	NULL
,	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Incubation	NULL
proceeded	NULL
at	NULL
37°C	NULL
for	NULL
24	NULL
hours	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
retreated	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
anti-Fas	NULL
antibody	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
32	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
Fas	NULL
sensitivity	NULL
,	NULL
1	NULL
ug/ml	NULL
of	NULL
anti-Fas	NULL
mAb	NULL
(	NULL
CH11	NULL
;	NULL
Kamiya	NULL
Biomedical	NULL
Corp.	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
or	NULL
in	NULL
some	NULL
experiments	NULL
purified	NULL
mouse	NULL
IgM	NULL
control	NULL
protein	NULL
(	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
was	NULL
added	NULL
.	NULL

Antisense	NULL
STAT	NULL
3	NULL
(	NULL
5-ACT	NULL
CAA	NULL
ACT	NULL
GCC	NULL
CTC	NULL
The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume	NULL
107	NULL
|_	NULL
Number	NULL
3	NULL
CTG	NULL
CT-3	NULL
``	NULL
)	NULL
or	NULL
control	NULL
oligonucleotide	NULL
(	NULL
5	NULL
``	NULL
-TCT	NULL
GGC	NULL
AAA	NULL
GTG	NULL
TCA	NULL
GTA	NULL
TG-3	NULL
'	NULL
)	NULL
(	NULL
Isis	NULL
Pharmaceuticals	NULL
Inc.	NULL
,	NULL
Carlsbad	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
)	NULL
was	NULL
added	NULL
at	NULL
the	NULL
concentrations	NULL
indicated	NULL
.	NULL

Oligonucleotides	NULL
were	NULL
synthesized	NULL
using	NULL
phosphorothioate	NULL
chemistry	NULL
,	NULL
and	NULL
2	NULL
'	NULL
``	NULL
-O-methoxyethyl	NULL
modification	NULL
of	NULL
the	NULL
five	NULL
terminal	NULL
nucleotides	NULL
(	NULL
under-lined	NULL
)	NULL
was	NULL
used	NULL
to	NULL
increase	NULL
stability	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
33	NULL
)	NULL
.	NULL

After	NULL
6	NULL
hours	NULL
without	NULL
sera	NULL
,	NULL
5	NULL
%	NULL
FBS	NULL
and	NULL
CH11	NULL
were	NULL
added	NULL
.	NULL

Incubation	NULL
continued	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
hours	NULL
before	NULL
collection	NULL
for	NULL
extract	NULL
preparation	NULL
and	NULL
apoptosis	NULL
analysis	NULL
.	NULL

For	NULL
experiments	NULL
with	NULL
the	NULL
caspase	NULL
inhibitor	NULL
(	NULL
Ac-DEVD-fmk	NULL
;	NULL
Calbiochem-Nov-abiochem	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
cells	NULL
were	NULL
pre-treated	NULL
for	NULL
4	NULL
hours	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
AG-490	NULL
.	NULL

Apoptosis	NULL
assay	NULL
.	NULL

To	NULL
measure	NULL
apoptosis	NULL
,	NULL
we	NULL
performed	NULL
two-color	NULL
flow	NULL
cytometry	NULL
with	NULL
7-amino-actinomycin	NULL
D	NULL
(	NULL
7-AAD	NULL
;	NULL
Calbiochem-Novabiochem	NULL
)	NULL
and	NULL
annexin-V-FITC	NULL
(	NULL
5	NULL
ul	NULL
;	NULL
CLONTECH	NULL
Laboratories	NULL
Inc.	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Data	NULL
acquisition	NULL
and	NULL
analysis	NULL
were	NULL
performed	NULL
by	NULL
the	NULL
Flow	NULL
Cytometry	NULL
Core	NULL
Facility	NULL
at	NULL
the	NULL
H.	NULL
Lee	NULL
Moffitt	NULL
Cancer	NULL
Center	NULL
.	NULL

The	NULL
peak	NULL
emission	NULL
for	NULL
7-AAD	NULL
is	NULL
approximately	NULL
685	NULL
nm	NULL
,	NULL
and	NULL
a	NULL
FL3	NULL
photomul-tiplier	NULL
tube	NULL
was	NULL
used	NULL
with	NULL
a	NULL
670-nm-long	NULL
pass	NULL
filter	NULL
.	NULL

No	NULL
distinction	NULL
was	NULL
made	NULL
between	NULL
intermediate	NULL
and	NULL
late	NULL
apoptosis	NULL
.	NULL

Any	NULL
7-AAD	NULL
single	NULL
positive	NULL
stained	NULL
cells	NULL
were	NULL
considered	NULL
necrotic	NULL
and	NULL
excluded	NULL
from	NULL
the	NULL
calculation	NULL
for	NULL
apoptosis	NULL
.	NULL

Forward	NULL
and	NULL
side	NULL
scatter	NULL
analyses	NULL
,	NULL
as	NULL
well	NULL
as	NULL
surface	NULL
staining	NULL
with	NULL
anti-CD45	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
were	NULL
used	NULL
to	NULL
identify	NULL
the	NULL
lymphocyte	NULL
population	NULL
in	NULL
peripheral	NULL
blood	NULL
samples	NULL
from	NULL
leukemic	NULL
LGLs	NULL
and	NULL
normal	NULL
PBMCs	NULL
.	NULL

This	NULL
lymphocyte	NULL
gate	NULL
was	NULL
then	NULL
used	NULL
to	NULL
examine	NULL
the	NULL
population	NULL
that	NULL
stained	NULL
positive	NULL
for	NULL
annexin-V-FITC	NULL
,	NULL
and	NULL
the	NULL
percent	NULL
specific	NULL
apoptosis	NULL
was	NULL
calculated	NULL
using	NULL
the	NULL
following	NULL
formula	NULL
:	NULL
[	NULL
(	NULL
%	NULL
annexin-V-FITC	NULL
positive	NULL
in	NULL
the	NULL
assay	NULL
well	NULL
)	NULL
-	NULL
(	NULL
%	NULL
annexin-V-FITC	NULL
positive	NULL
in	NULL
the	NULL
control	NULL
well	NULL
)	NULL
x	NULL
100	NULL
]	NULL
+	NULL
[	NULL
100	NULL
-	NULL
(	NULL
%	NULL
annexin-V-FITC	NULL
positive	NULL
in	NULL
the	NULL
control	NULL
well	NULL
)	NULL
]	NULL
For	NULL
three-color	NULL
flow	NULL
cytometry	NULL
,	NULL
leukemic	NULL
LGLs	NULL
were	NULL
first	NULL
stained	NULL
with	NULL
5	NULL
ul	NULL
of	NULL
anti-CD8-PE	NULL
(	NULL
Coulter	NULL
Corp.	NULL
,	NULL
Miami	NULL
,	NULL
Florida	NULL
,	NULL
USA	NULL
)	NULL
for	NULL
30	NULL
minutes	NULL
on	NULL
ice	NULL
in	NULL
the	NULL
dark	NULL
,	NULL
washed	NULL
two	NULL
times	NULL
in	NULL
1	NULL
x	NULL
PBS	NULL
and	NULL
stained	NULL
with	NULL
7-AAD	NULL
and	NULL
annexin-V-FITC	NULL
.	NULL

Western	NULL
immunoblotting	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
a	NULL
buffer	NULL
composed	NULL
of	NULL
50	NULL
mM	NULL
Tris-Cl	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
;	NULL
5	NULL
mM	NULL
EDTA	NULL
;	NULL
150	NULL
mM	NULL
NaCl	NULL
;	NULL
0.5	NULL
%	NULL
NP-40	NULL
;	NULL
0.5	NULL
%	NULL
Triton-X-100	NULL
(	NULL
RIPA	NULL
)	NULL
containing	NULL
1	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
aprotinin	NULL
,	NULL
and	NULL
antipain	NULL
;	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
;	NULL
and	NULL
0.5	NULL
mM	NULL
PMSF	NULL
(	NULL
all	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
determined	NULL
in	NULL
all	NULL
cell	NULL
extracts	NULL
using	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Hercules	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Unless	NULL
otherwise	NULL
indicated	NULL
,	NULL
25	NULL
ug	NULL
of	NULL
total	NULL
protein	NULL
was	NULL
loaded	NULL
per	NULL
lane	NULL
in	NULL
Laemmli	NULL
SDS-PAGE	NULL
sample	NULL
loading	NULL
buffer	NULL
and	NULL
boiled	NULL
for	NULL
5	NULL
minutes	NULL
before	NULL
separation	NULL
by	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
.	NULL

Twenty-five	NULL
micrograms	NULL
of	NULL
total	NULL
protein	NULL
was	NULL
found	NULL
to	NULL
give	NULL
ECL	NULL
signals	NULL
within	NULL
the	NULL
linear	NULL
range	NULL
for	NULL
B-actin	NULL
in	NULL
titration	NULL
experiments	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
then	NULL
transferred	NULL
to	NULL
a	NULL
membrane	NULL
for	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Antibodies	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
following	NULL
sources	NULL
and	NULL
used	NULL
at	NULL
the	NULL
dilutions	NULL
recommended	NULL
by	NULL
the	NULL
manu-	NULL
facturer	NULL
:	NULL
Bel-2	NULL
,	NULL
Mcl-1	NULL
,	NULL
STAT1	NULL
,	NULL
and	NULL
Bcl-x	NULL
;	NULL
antibodies	NULL
,	NULL
1:1,000	NULL
dilution	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
)	NULL
,	NULL
anti-STAT3	NULL
,	NULL
1:2,000	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
)	NULL
,	NULL
and	NULL
anti-B-actin	NULL
1:2,500	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Antibody	NULL
detection	NULL
was	NULL
performed	NULL
by	NULL
standard	NULL
ECL	NULL
techniques	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Amersham	NULL
Phar-macia	NULL
Biotech	NULL
)	NULL
.	NULL

Protein	NULL
quantification	NULL
was	NULL
performed	NULL
by	NULL
densitometry	NULL
using	NULL
the	NULL
ImageQuant	NULL
program	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
California	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Transient	NULL
transfection	NULL
assay	NULL
.	NULL

A	NULL
luciferase	NULL
reporter	NULL
(	NULL
p-203/+10mecl-1-luc	NULL
)	NULL
driven	NULL
by	NULL
the	NULL
murine	NULL
mel-1	NULL
promoter	NULL
region	NULL
(	NULL
-203	NULL
to	NULL
+10	NULL
)	NULL
and	NULL
an	NULL
identical	NULL
reporter	NULL
with	NULL
a	NULL
mutated	NULL
SIE	NULL
site	NULL
(	NULL
p-203/+10mS	NULL
)	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

The	NULL
pLucSRE-luciferase	NULL
was	NULL
included	NULL
as	NULL
a	NULL
reporter	NULL
control	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
indicated	NULL
plasmids	NULL
into	NULL
NIH3T3	NULL
cells	NULL
was	NULL
performed	NULL
using	NULL
CaPO04	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
28	NULL
)	NULL
.	NULL

pM-v-src	NULL
and	NULL
pSGS-STAT	NULL
3B	NULL
are	NULL
plasmid	NULL
vectors	NULL
expressing	NULL
v-sre	NULL
and	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
STAT3	NULL
,	NULL
respectively	NULL
.	NULL

Control	NULL
transfections	NULL
were	NULL
also	NULL
performed	NULL
using	NULL
pSG5	NULL
to	NULL
assess	NULL
whether	NULL
nonspecific	NULL
repression	NULL
occurred	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
vector	NULL
alone	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
normalized	NULL
by	NULL
expression	NULL
of	NULL
a	NULL
CMV-B-galactosidase	NULL
reporter	NULL
gene	NULL
.	NULL

Statistical	NULL
analysis	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
A.	NULL
Cantor	NULL
(	NULL
Biostatistic	NULL
Core	NULL
,	NULL
H.	NULL
Lee	NULL
Moffitt	NULL
Cancer	NULL
Cen-ter	NULL
)	NULL
using	NULL
the	NULL
SAS	NULL
statistical	NULL
software	NULL
program	NULL
(	NULL
SAS	NULL
Institute	NULL
Inc.	NULL
,	NULL
Cary	NULL
,	NULL
North	NULL
Carolina	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Results	NULL
Leukemic	NULL
LGL	NULL
s	NULL
display	NULL
constitutively	NULL
activated	NULL
STAT3	NULL
and/or	NULL
STAT1	NULL
.	NULL

EMSA	NULL
using	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
containing	NULL
a	NULL
high-affinity	NULL
mutant	NULL
of	NULL
the	NULL
STAT-specific	NULL
DNA	NULL
sequence	NULL
from	NULL
the	NULL
hSIE	NULL
is	NULL
used	NULL
to	NULL
detect	NULL
homodimers	NULL
and	NULL
heterodimers	NULL
of	NULL
STAT3	NULL
and	NULL
STAT1	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
PBMCs	NULL
of	NULL
19	NULL
LGL	NULL
leukemia	NULL
patients	NULL
.	NULL

The	NULL
diagnosis	NULL
was	NULL
confirmed	NULL
on	NULL
all	NULL
patients	NULL
by	NULL
TCR	NULL
gene	NULL
rearrangement	NULL
studies	NULL
,	NULL
and	NULL
the	NULL
leukemic	NULL
cells	NULL
constituted	NULL
70-90	NULL
%	NULL
of	NULL
lymphocytes	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

We	NULL
found	NULL
that	NULL
nuclear	NULL
extracts	NULL
from	NULL
all	NULL
19	NULL
patients	NULL
contained	NULL
DNA-binding	NULL
complexes	NULL
that	NULL
recognized	NULL
the	NULL
hSIE	NULL
probe	NULL
(	NULL
results	NULL
from	NULL
12	NULL
patients	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
1a	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
previously	NULL
reported	NULL
data	NULL
,	NULL
little	NULL
or	NULL
no	NULL
SIE-DNA-binding	NULL
activity	NULL
was	NULL
detected	NULL
with	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
five	NULL
normal	NULL
donors	NULL
(	NULL
Figure	NULL
1a	NULL
,	NULL
lanes	NULL
1-5	NULL
)	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Normal	NULL
PBMCs	NULL
treated	NULL
for	NULL
7	NULL
days	NULL
with	NULL
PHA	NULL
+	NULL
IL-2	NULL
(	NULL
activated	NULL
normal	NULL
)	NULL
,	NULL
however	NULL
,	NULL
contained	NULL
robust	NULL
SIE-binding	NULL
activity	NULL
(	NULL
Figure	NULL
1a	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
STAT	NULL
3	NULL
protein	NULL
expression	NULL
was	NULL
also	NULL
examined	NULL
in	NULL
leukemic	NULL
LGLs	NULL
from	NULL
each	NULL
sample	NULL
and	NULL
in	NULL
the	NULL
normal	NULL
PBMCs	NULL
(	NULL
Figure	NULL
1a	NULL
,	NULL
top	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
increased	NULL
STAT3	NULL
DNA-binding	NULL
activity	NULL
observed	NULL
in	NULL
leukemic	NULL
LGLs	NULL
by	NULL
EMSA	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
amount	NULL
of	NULL
STAT	NULL
3	NULL
protein	NULL
was	NULL
higher	NULL
in	NULL
leukemic	NULL
LGLs	NULL
and	NULL
activated	NULL
normal	NULL
PBMCs	NULL
compared	NULL
with	NULL
the	NULL
amount	NULL
in	NULL
unstimulated	NULL
normal	NULL
PBMCs	NULL
,	NULL
suggesting	NULL
continued	NULL
activation	NULL
in	NULL
leukemic	NULL
cells	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
a	NULL
and	NULL
c	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
STAT	NULL
family	NULL
members	NULL
bound	NULL
to	NULL
the	NULL
SIE	NULL
probe	NULL
in	NULL
leukemic	NULL
LGL	NULL
,	NULL
we	NULL
performed	NULL
blocking	NULL
or	NULL
The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume	NULL
107	NULL
|	NULL
Number	NULL
3	NULL
353	NULL
°	NULL
g	NULL
¢	NULL
¢	NULL
E83	NULL
t	NULL
o	NULL
10013	NULL
10104	NULL
10007	NULL
10200	NULL
10201	NULL
-o	NULL
ror	NULL
ort	NULL
r	NULL
Qr-r	NULL
o	NULL
o	NULL
-	NULL
0	NULL
-	NULL
0	NULL
-	NULL
0	NULL
-	NULL
c	NULL
-	NULL
c	NULL
O	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
06	NULL
o	NULL
o	NULL
6	NULL
o	NULL
i-	NULL
b-	NULL
-	NULL
I-	NULL
i-	NULL
i-	NULL
-	NULL
|-	NULL
-	NULL
|-5	NULL
00	NULL
n	NULL
I	NULL
T	NULL
n	NULL
a	NULL
t	NULL
t	NULL
G	NULL
T	NULL
G	NULL
<	NULL
&	NULL
o	NULL
&	NULL
o	NULL
&	NULL
o	NULL
&	NULL
o	NULL
&	NULL
t	NULL
10°35	NULL
aa	NULL
dadadada	NULL
dd	NULL
dd	NULL
-	NULL
$	NULL
|	NULL
6	NULL
60	NULL
16	NULL
60	NULL
1	NULL
6	NULL
60	NULL
1	NULL
6	NULL
6	NULL
&	NULL
0	NULL
1	NULL
6	NULL
6	NULL
2	NULL
222	NULL
22	NULL
999999999999	NULL
;	NULL
'	NULL
acdke	NULL
=	NULL
wae	NULL
|	NULL
=	NULL
use	NULL
mme	NULL
me	NULL
-	NULL
cae	NULL
mee	NULL
o	NULL
>	NULL
—-———_	NULL
‘	NULL
.|	NULL
t	NULL
u	NULL
WB	NULL
anti-STAT3	NULL
g	NULL
,	NULL
——	NULL
EMSA	NULL
hSIE	NULL
Probe	NULL
—|	NULL
<	NULL
..	NULL
'	NULL
l	NULL
-ST3:3	NULL
j	NULL
3	NULL
|	NULL
a	NULL
\	NULL
iw	NULL
-ST1:3	NULL
W	NULL
-=ST	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6000	NULL
7	NULL
8	NULL
900	NULL
10	NULL
11120	NULL
18	NULL
1415	NULL
-ST33	NULL
-	NULL
¢	NULL
NL	NULL
Leukemic	NULL
LGL	NULL
-	NULL
ST1:3	NULL
6	NULL
-S	NULL
a	NULL
+	NULL
$	NULL
&	NULL
8	NULL
§	NULL
5	NULL
8	NULL
§	NULL
?	NULL

g	NULL
1	NULL
L1	NULL
1	NULL
5	NULL
g	NULL
8	NULL
g	NULL
0	NULL
8	NULL
o	NULL
§	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
2	NULL
3	NULL
P	NULL
wz	NULL
w	NULL
»	NULL
--	NULL
i	NULL
*	NULL
anti-PO	NULL
,	NULL
-ST3	NULL
c	NULL
.	NULL

2	NULL
Ne	NULL
see	NULL
mme	NULL
suse	NULL
cue	NULL
sume	NULL
==	NULL
anti-ST3	NULL
5	NULL
S	NULL
&	NULL
5	NULL
vore	NULL
CH	NULL
elgg	NULL
o	NULL
>	NULL
comer	NULL
cames	NULL
Cutt	NULL
~*~	NULL
anti-B-actin	NULL
C	NULL
10	NULL
2	NULL
8	NULL
40	NULL
50	NULL
60	NULL
70	NULL
80	NULL
9	NULL
40	NULL
11	NULL
d	NULL
NL	NULL
Leukemic	NULL
LGL	NULL
o	NULL
0	NULL
O	NULL
<	NULL
3	NULL
<	NULL
h	NULL
®	NULL
©	NULL
G0	NULL
t	NULL
o	NULL
w	NULL
o	NULL
s	NULL
°	NULL
18959	NULL
§	NULL
5388858	NULL
8	NULL
Q	NULL
.	NULL

_	NULL
_u	NULL
_u	NULL
_	NULL
5	NULL
s	NULL
o	NULL
2222	NULL
2	NULL
2	NULL
22	NULL
22°	NULL
2	NULL
2	NULL
2	NULL
L	NULL
G	NULL
h	NULL
-ST5:5	NULL
<	NULL
3	NULL
-=ST1	NULL
LL	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
1112	NULL
13	NULL
Figure	NULL
1	NULL
Activation	NULL
of	NULL
STAT3	NULL
and	NULL
STAT1	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

(	NULL
a	NULL
)	NULL
EMSA	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBMCs	NULL
of	NULL
normal	NULL
donors	NULL
(	NULL
NL	NULL
)	NULL
,	NULL
from	NULL
normal	NULL
donors	NULL
activated	NULL
for	NULL
7	NULL
days	NULL
with	NULL
PHA	NULL
+	NULL
IL-2	NULL
(	NULL
NL-AC	NULL
)	NULL
,	NULL
and	NULL
from	NULL
patients	NULL
with	NULL
LGL	NULL
leukemia	NULL
(	NULL
LGL	NULL
)	NULL
.	NULL

Cytoplasmic	NULL
extracts	NULL
from	NULL
each	NULL
sample	NULL
were	NULL
run	NULL
on	NULL
an	NULL
SDS-PAGE	NULL
gel	NULL
and	NULL
blotted	NULL
for	NULL
expression	NULL
of	NULL
STAT3	NULL
.	NULL

(	NULL
b	NULL
)	NULL
EMSA	NULL
supershift	NULL
or	NULL
blocking	NULL
experiments	NULL
with	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
10	NULL
,	NULL
and	NULL
13	NULL
)	NULL
,	NULL
anti-STAT1-preincubated	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
11	NULL
,	NULL
and	NULL
14	NULL
)	NULL
,	NULL
and	NULL
anti-STAT3-preincubated	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
12	NULL
,	NULL
and	NULL
15	NULL
)	NULL
reaction	NULL
mixtures	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
whole-cell	NULL
extracts	NULL
for	NULL
phosphorylated	NULL
STAT3	NULL
,	NULL
total	NULL
STAT3	NULL
,	NULL
and	NULL
B-actin	NULL
.	NULL

(	NULL
d	NULL
)	NULL
EMSA	NULL
for	NULL
STAT5-DNA-binding	NULL
activity	NULL
with	NULL
activated	NULL
normal	NULL
and	NULL
leukemic	NULL
LGLs	NULL
(	NULL
10024-AC	NULL
)	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

The	NULL
relative	NULL
migration	NULL
of	NULL
STAT3:3	NULL
homodimers	NULL
(	NULL
ST3:3	NULL
)	NULL
,	NULL
STAT1:3	NULL
heterodimers	NULL
(	NULL
ST1:3	NULL
)	NULL
,	NULL
and	NULL
STAT1:1	NULL
homodimers	NULL
(	NULL
ST1:1	NULL
)	NULL
is	NULL
shown	NULL
in	NULL
a	NULL
and	NULL
b	NULL
.	NULL

(	NULL
d	NULL
)	NULL
STATS:5	NULL
homodimers	NULL
(	NULL
ST5:5	NULL
)	NULL
and	NULL
STAT1:1	NULL
homodimers	NULL
(	NULL
ST1:1	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

WB	NULL
,	NULL
Western	NULL
blot	NULL
.	NULL

354	NULL
supershift	NULL
analyses	NULL
with	NULL
anti-STAT1	NULL
and	NULL
3	NULL
specific	NULL
antibodies	NULL
,	NULL
respectively	NULL
.	NULL

Supershift	NULL
data	NULL
for	NULL
five	NULL
patients	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
1b	NULL
and	NULL
demonstrate	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
SIE-binding	NULL
activity	NULL
consisted	NULL
of	NULL
STAT	NULL
3:3	NULL
homodimers	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
STAT1:1	NULL
homodimers	NULL
and	NULL
STAT1:3	NULL
heterodimers	NULL
.	NULL

An	NULL
anti-STAT1	NULL
blocking	NULL
antibody	NULL
completely	NULL
eliminated	NULL
the	NULL
complex	NULL
observed	NULL
in	NULL
extracts	NULL
from	NULL
one	NULL
patient	NULL
with	NULL
LGL	NULL
leukemia	NULL
(	NULL
no	NULL
.	NULL

10104	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
activated	NULL
STAT1:1	NULL
homodimers	NULL
(	NULL
Figure	NULL
1b	NULL
,	NULL
lanes	NULL
4-6	NULL
)	NULL
.	NULL

This	NULL
patient	NULL
's	NULL
cells	NULL
displayed	NULL
a	NULL
slightly	NULL
different	NULL
phenotype	NULL
,	NULL
being	NULL
double	NULL
CD4/CD8*	NULL
rather	NULL
than	NULL
the	NULL
usual	NULL
CD8*/CD4-	NULL
seen	NULL
in	NULL
leukemic	NULL
LGLs	NULL
from	NULL
all	NULL
other	NULL
patients	NULL
.	NULL

The	NULL
dimerization	NULL
and	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
STAT3	NULL
are	NULL
dependent	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
phosphorylation	NULL
status	NULL
of	NULL
STAT3	NULL
was	NULL
examined	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
a	NULL
phosphoryla-tion-specific	NULL
STAT3	NULL
antibody	NULL
(	NULL
Figure	NULL
1c	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
leukemic	NULL
LGL	NULL
from	NULL
seven	NULL
patients	NULL
,	NULL
PHA+IL-	NULL
2-activated	NULL
PBMCs	NULL
,	NULL
and	NULL
U266	NULL
cells	NULL
displayed	NULL
varying	NULL
amounts	NULL
of	NULL
constitutively	NULL
phosphorylated	NULL
STAT3	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
normal	NULL
unactivated	NULL
PBMCs	NULL
displayed	NULL
no	NULL
detectable	NULL
constitutively	NULL
phosphorylated	NULL
STAT3	NULL
.	NULL

These	NULL
data	NULL
further	NULL
confirm	NULL
the	NULL
EMSA	NULL
results	NULL
suggesting	NULL
that	NULL
constitutively	NULL
activated	NULL
STAT	NULL
3	NULL
is	NULL
present	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

STAT5-DNA	NULL
binding	NULL
is	NULL
induced	NULL
after	NULL
TCR	NULL
stimulation	NULL
of	NULL
normal	NULL
T	NULL
lymphocytes	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Because	NULL
leukemic	NULL
LGLs	NULL
share	NULL
many	NULL
characteristics	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
examined	NULL
STAT5	NULL
DNA	NULL
binding	NULL
activity	NULL
using	NULL
an	NULL
oligonucleotide	NULL
probe	NULL
containing	NULL
the	NULL
mammary	NULL
gland	NULL
factor	NULL
element	NULL
(	NULL
MGFe	NULL
)	NULL
that	NULL
recognizes	NULL
STATS	NULL
and	NULL
STAT1	NULL
homodimers	NULL
(	NULL
31	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
treatment	NULL
with	NULL
IL-2	NULL
+	NULL
PHA	NULL
resulted	NULL
in	NULL
strong	NULL
activation	NULL
of	NULL
STAT	NULL
5	NULL
in	NULL
both	NULL
normal	NULL
activated	NULL
PBMCs	NULL
and	NULL
inactivated	NULL
leukemic	NULL
LGLs	NULL
(	NULL
Figure	NULL
1d	NULL
)	NULL
but	NULL
that	NULL
constitutive	NULL
STAT5	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
leukemic	NULL
LGLs	NULL
from	NULL
only	NULL
two	NULL
of	NULL
12	NULL
patients	NULL
(	NULL
data	NULL
shown	NULL
for	NULL
eight	NULL
patients	NULL
)	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume	NULL
107	NULL
|_	NULL
Number	NULL
3	NULL
JAK-family	NULL
kinase	NULL
inhibitor	NULL
induces	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGL	NULL
.	NULL

We	NULL
previously	NULL
demonstrated	NULL
that	NULL
leukemic	NULL
LGLs	NULL
display	NULL
resistance	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
multiple	NULL
myeloma	NULL
cell	NULL
line	NULL
U266	NULL
expressed	NULL
constitutively	NULL
activated	NULL
STAT3	NULL
and	NULL
demonstrated	NULL
Fas	NULL
resistance	NULL
that	NULL
was	NULL
reversed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
selective	NULL
JAK	NULL
inhibitor	NULL
,	NULL
AG-490	NULL
(	NULL
9	NULL
)	NULL
.	NULL

We	NULL
first	NULL
examined	NULL
the	NULL
apoptotic	NULL
inducing	NULL
effects	NULL
of	NULL
AG-490	NULL
on	NULL
leukemic	NULL
LGLs	NULL
(	NULL
patient	NULL
10160	NULL
)	NULL
,	NULL
normal	NULL
unactivated	NULL
PBMCs	NULL
,	NULL
normal	NULL
PHA+IL-2-activated	NULL
PBMCs	NULL
,	NULL
and	NULL
U266	NULL
cells	NULL
.	NULL

Normal	NULL
unactivated	NULL
PBMCs	NULL
,	NULL
leukemic	NULL
LGLs	NULL
,	NULL
and	NULL
U266	NULL
cells	NULL
displayed	NULL
inherent	NULL
resistance	NULL
to	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
(	NULL
Figure	NULL
2a	NULL
)	NULL
.	NULL

AG-490	NULL
alone	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
annexin-V-FITC	NULL
binding	NULL
in	NULL
leukemic	NULL
LGLs	NULL
(	NULL
patient	NULL
10160	NULL
)	NULL
after	NULL
48	NULL
hours	NULL
(	NULL
Figure	NULL
2a	NULL
,	NULL
row	NULL
1	NULL
)	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
CH11	NULL
and	NULL
AG-490	NULL
further	NULL
enhanced	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGL	NULL
from	NULL
patient	NULL
10160	NULL
,	NULL
in	NULL
normal	NULL
activated	NULL
PBMCs	NULL
,	NULL
and	NULL
in	NULL
U266	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
leukemic	NULL
LGLs	NULL
,	NULL
normal	NULL
unactivated	NULL
PBMCs	NULL
displayed	NULL
no	NULL
increase	NULL
in	NULL
apoptosis	NULL
in	NULL
response	NULL
to	NULL
either	NULL
AG-490	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
anti-Fas	NULL
mAb	NULL
.	NULL

Figure	NULL
2b	NULL
demonstrates	NULL
that	NULL
increasing	NULL
doses	NULL
of	NULL
AG-490	NULL
induced	NULL
a	NULL
dose-dependent	NULL
increase	NULL
in	NULL
the	NULL
percent	NULL
specific	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGLs	NULL
but	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
normal	NULL
PBMCs	NULL
(	NULL
Figure	NULL
2b	NULL
)	NULL
.	NULL

The	NULL
50	NULL
LM	NULL
dose	NULL
of	NULL
AG-490	NULL
was	NULL
then	NULL
subsequently	NULL
chosen	NULL
for	NULL
the	NULL
remaining	NULL
experiments	NULL
owing	NULL
to	NULL
the	NULL
greater	NULL
differential	NULL
effect	NULL
between	NULL
leukemic	NULL
LGLs	NULL
and	NULL
normal	NULL
PBMCs	NULL
.	NULL

We	NULL
then	NULL
examined	NULL
leukemic	NULL
LGL	NULL
from	NULL
11	NULL
patients	NULL
and	NULL
PBMCs	NULL
from	NULL
three	NULL
normal	NULL
donors	NULL
to	NULL
determine	NULL
whether	NULL
AG-490	NULL
treatment	NULL
consistently	NULL
induced	NULL
apoptosis	NULL
and	NULL
Fas	NULL
sensitivity	NULL
.	NULL

We	NULL
found	NULL
that	NULL
AG-490	NULL
treatment	NULL
induced	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGL	NULL
from	NULL
all	NULL
11	NULL
patients	NULL
tested	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
results	NULL
with	NULL
normal	NULL
unactivated	NULL
PBMCs	NULL
(	NULL
Figure	NULL
3a	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-Fas	NULL
agonistic	NULL
mAb	NULL
CH11	NULL
,	NULL
however	NULL
,	NULL
produced	NULL
variable	NULL
results	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
results	NULL
in	NULL
U266	NULL
cells	NULL
,	NULL
leukemic	NULL
LGLs	NULL
from	NULL
patients	NULL
10160	NULL
and	NULL
10128	NULL
displayed	NULL
reversal	NULL
of	NULL
Fas	NULL
resistance	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
an	NULL
additive	NULL
induction	NULL
of	NULL
apoptosis	NULL
after	NULL
both	NULL
AG-490	NULL
and	NULL
CH11	NULL
treatment	NULL
.	NULL

Leukemic	NULL
LGLs	NULL
from	NULL
the	NULL
remaining	NULL
nine	NULL
patients	NULL
demonstrated	NULL
no	NULL
effect	NULL
or	NULL
a	NULL
decrease	NULL
in	NULL
apoptotic	NULL
cells	NULL
after	NULL
the	NULL
combination	NULL
of	NULL
AG-490	NULL
and	NULL
CH11	NULL
.	NULL

Approximately	NULL
70	NULL
%	NULL
of	NULL
the	NULL
circulating	NULL
PBMCs	NULL
in	NULL
most	NULL
patients	NULL
with	NULL
leukemic	NULL
LGLs	NULL
are	NULL
CD8*	NULL
T	NULL
lymphocytes	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
only	NULL
the	NULL
leukemic	NULL
LGL	NULL
cells	NULL
(	NULL
CD8*	NULL
)	NULL
undergo	NULL
apoptosis	NULL
and	NULL
not	NULL
the	NULL
nonleukemic	NULL
(	NULL
CD8-	NULL
)	NULL
cells	NULL
,	NULL
we	NULL
performed	NULL
three-color	NULL
flow	NULL
cytometry	NULL
analyses	NULL
with	NULL
annexin-V-FITC	NULL
,	NULL
7-AAD	NULL
,	NULL
and	NULL
A	NULL
DMSO	NULL
CH11	NULL
AG-490	NULL
AG-490+CH11	NULL
80	NULL
3	NULL
B	NULL
®	NULL
B	NULL
70	NULL
)	NULL
-	NULL
#	NULL
-	NULL
LGL	NULL
A	NULL
e	NULL
255	NULL
4	NULL
35	NULL
M	NULL
M	NULL
L_	NULL
--	NULL
@	NULL
--	NULL
-	NULL
NL	NULL
B	NULL
5	NULL
m	NULL
e	NULL
2	NULL
s	NULL
12	NULL
,	NULL
T.	NULL
,	NULL
al	NULL
E	NULL
,	NULL
3	NULL
&	NULL
60	NULL
48	NULL
4°	NULL
&	NULL
=	NULL
q=	NULL
a	NULL
»	NULL
kes	NULL
Ira	NULL
0	NULL
)	NULL
«	NULL
2	NULL
s	NULL
*s	NULL
*s	NULL
o	NULL
&	NULL
8	NULL
50	NULL
C	NULL
la	NULL
=	NULL
+5	NULL
©	NULL
:	NULL
©	NULL
s	NULL
©	NULL
a	NULL
®	NULL
B	NULL
``	NULL
®	NULL
amie	NULL
af	NULL
.	NULL

a	NULL
}	NULL
8	NULL
``	NULL
oo	NULL
aon	NULL
40	NULL
igs	NULL
ace	NULL
190	NULL
dor	NULL
aot	NULL
do	NULL
aot	NULL
Tot	NULL
108	NULL
408	NULL
tof	NULL
a	NULL
.	NULL

40	NULL
FL1H	NULL
FL1-H	NULL
FL1-H	NULL
G	NULL
:	NULL
B3	NULL
E	NULL
%	NULL
2	NULL
s	NULL
B	NULL
&	NULL
6	NULL
30	NULL
16	NULL
4	NULL
14	NULL
M	NULL
ims	NULL
tar	NULL
:	NULL
|	NULL
,	NULL
,	NULL
16.6	NULL
t	NULL
24	NULL
m	NULL
'	NULL
5	NULL
B	NULL
&	NULL
h	NULL
.	NULL

h	NULL
8	NULL
r	NULL
T.	NULL
T4	NULL
E\	NULL
Z	NULL
aA	NULL
20	NULL
24	NULL
%	NULL
a=	NULL
3°	NULL
6	NULL
m	NULL
®	NULL
p	NULL
2	NULL
271	NULL
,	NULL
@	NULL
``	NULL
h	NULL
P	NULL
A	NULL
of	NULL
?	NULL

°r	NULL
°	NULL
10	NULL
@	NULL
-	NULL
--	NULL
=	NULL
if	NULL
i	NULL
F	NULL
uC	NULL
.	NULL

P	NULL
12	NULL
B	NULL
;	NULL
p	NULL
E	NULL
”	NULL
-..	NULL
&	NULL
om	NULL
i	NULL
lan	NULL
o	NULL
105	NULL
aot	NULL
740	NULL
)	NULL
don	NULL
agt	NULL
o	NULL
>	NULL
aot	NULL
7	NULL
aot	NULL
rot	NULL
aot	NULL
aot	NULL
Cage	NULL
aon	NULL
02	NULL
dot	NULL
D-	NULL
FL1H	NULL
FL1-H	NULL
FL1H	NULL
0	NULL
€	NULL
55	NULL
50	NULL
100	NULL
&	NULL
las	NULL
tas	NULL
|	NULL
°	NULL
s	NULL
fas	NULL
|	NULL
°	NULL
atas	NULL
|	NULL
°	NULL
sa	NULL
+	NULL
35	NULL
``	NULL
®	NULL
B	NULL
B	NULL
B	NULL
z	NULL
Dose	NULL
of	NULL
AG-490	NULL
(	NULL
uM	NULL
)	NULL
Ts	NULL
T.	NULL
T4	NULL
Ts	NULL
u	NULL
3	NULL
$	NULL
9	NULL
4°	NULL
42	NULL
%	NULL
48	NULL
fa	NULL
s	NULL
LLB	NULL
LLB	NULL
LLB	NULL
8	NULL
B	NULL
:	NULL
a	NULL
-	NULL
p	NULL
:	NULL
100	NULL
do	NULL
108	NULL
dot	NULL
dot	NULL
``	NULL
ast	NULL
dot	NULL
_	NULL
102	NULL
405	NULL
108	NULL
10°	NULL
aot	NULL
aot	NULL
7400	NULL
dor	NULL
_	NULL
102	NULL
aos	NULL
dof	NULL
FL1H	NULL
FL1H	NULL
FL1-H	NULL
FL1-H	NULL
&	NULL
165	NULL
f	NULL
21	NULL
h	NULL
27	NULL
t	NULL
84	NULL
h	NULL
es	NULL
t	NULL
14	NULL
=	NULL
ao	NULL
+	NULL
7.0	NULL
|	NULL
B	NULL
¢	NULL
¢	NULL
¢	NULL
4	NULL
%	NULL
T4	NULL
T4	NULL
Ts	NULL
S	NULL
Pe	NULL
&	NULL
e	NULL
42	NULL
lest	NULL
2	NULL
%	NULL
-	NULL
-	NULL
Pu	NULL
I_	NULL
m_	NULL
m_	NULL
&	NULL
_	NULL
&	NULL
e	NULL
e	NULL
e	NULL
e	NULL
-	NULL
eet	NULL
-	NULL
.	NULL

eRe	NULL
t	NULL
.	NULL

,	NULL
Bas	NULL
c-	NULL
®	NULL
(	NULL
R*	NULL
.	NULL

``	NULL
400	NULL
dot	NULL
_	NULL
40°	NULL
10°	NULL
10°	NULL
10°	NULL
40	NULL
10	NULL
10°	NULL
.	NULL

10°	NULL
109	NULL
10	NULL
``	NULL
10°	NULL
10f	NULL
100	NULL
10	NULL
108	NULL
103	NULL
10°	NULL
FL1H	NULL
FL1-H	NULL
FI	NULL
FL1-H	NULL
Annexin-V-FITC	NULL
Figure	NULL
2	NULL
AG-490	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Analysis	NULL
of	NULL
apoptosis	NULL
was	NULL
assessed	NULL
by	NULL
annexin-V-FITC	NULL
and	NULL
7-AAD	NULL
binding	NULL
in	NULL
PBMCs	NULL
isolated	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
LGL	NULL
leukemia	NULL
(	NULL
no	NULL
.	NULL

10160	NULL
;	NULL
row	NULL
1	NULL
)	NULL
,	NULL
from	NULL
a	NULL
normal	NULL
unactivated	NULL
donor	NULL
(	NULL
NL-7	NULL
;	NULL
row	NULL
2	NULL
)	NULL
,	NULL
from	NULL
activated	NULL
normal	NULL
PBMCs	NULL
(	NULL
NL-ZAC	NULL
;	NULL
row	NULL
3	NULL
)	NULL
or	NULL
from	NULL
the	NULL
U266	NULL
cell	NULL
line	NULL
(	NULL
row	NULL
4	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
+	NULL
mouse	NULL
IgM	NULL
(	NULL
drug	NULL
solvent	NULL
;	NULL
column	NULL
1	NULL
)	NULL
,	NULL
anti-Fas	NULL
agonistic	NULL
antibody	NULL
(	NULL
CH	NULL
11	NULL
;	NULL
column	NULL
2	NULL
)	NULL
,	NULL
50	NULL
uM	NULL
of	NULL
AG-490	NULL
+	NULL
mouse	NULL
IgM	NULL
(	NULL
column	NULL
3	NULL
)	NULL
,	NULL
or	NULL
AG-490	NULL
in	NULL
combination	NULL
with	NULL
CH11	NULL
(	NULL
column	NULL
4	NULL
)	NULL
.	NULL

The	NULL
average	NULL
percent	NULL
of	NULL
annexin-V-FTIC-positive	NULL
cells	NULL
and	NULL
SD	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
is	NULL
shown	NULL
in	NULL
the	NULL
upper	NULL
right	NULL
corner	NULL
of	NULL
the	NULL
histogram	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Annexin-V-FITC	NULL
binding	NULL
of	NULL
leukemic	NULL
LGL	NULL
and	NULL
normal	NULL
PBMCs	NULL
in	NULL
response	NULL
to	NULL
DMSO	NULL
(	NULL
0	NULL
)	NULL
and	NULL
AG-490	NULL
(	NULL
25	NULL
,	NULL
50	NULL
,	NULL
and	NULL
100	NULL
M	NULL
for	NULL
48	NULL
hours	NULL
)	NULL
.	NULL

The	NULL
percent	NULL
specific	NULL
apoptosis	NULL
is	NULL
indicative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
using	NULL
the	NULL
same	NULL
patient	NULL
.	NULL

AStatistically	NULL
significant	NULL
;	NULL
P	NULL
<	NULL
0.05	NULL
using	NULL
a	NULL
Student	NULL
's	NULL
¢	NULL
test	NULL
.	NULL

P	NULL
value	NULL
of	NULL
normal	NULL
unactivated	NULL
PBMCs	NULL
with	NULL
100	NULL
uM	NULL
approached	NULL
significance	NULL
(	NULL
P	NULL
=	NULL
0.06	NULL
)	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February2001	NULL
|	NULL
Volume107	NULL
|	NULL
Number3	NULL
355	NULL
Figure	NULL
3	NULL
AG-490	NULL
consistently	NULL
induced	NULL
annexin-V-FITC	NULL
binding	NULL
in	NULL
leukemic	NULL
LGLs	NULL
but	NULL
not	NULL
sensitization	NULL
of	NULL
Fas	NULL
.	NULL

(	NULL
a	NULL
)	NULL
The	NULL
percent	NULL
specific	NULL
apoptosis	NULL
was	NULL
calculated	NULL
for	NULL
normal	NULL
PBMCs	NULL
(	NULL
NL	NULL
)	NULL
,	NULL
leukemic	NULL
LGLs	NULL
(	NULL
patient	NULL
number	NULL
)	NULL
,	NULL
and	NULL
U266	NULL
cells	NULL
after	NULL
treatment	NULL
with	NULL
DMSO	NULL
.	NULL

Open	NULL
bars	NULL
,	NULL
anti-Fas	NULL
(	NULL
CH11	NULL
)	NULL
;	NULL
gray	NULL
bars	NULL
,	NULL
50	NULL
uM	NULL
AG-490	NULL
(	NULL
AG	NULL
)	NULL
;	NULL
filled	NULL
bars	NULL
,	NULL
AG-490	NULL
with	NULL
CH11	NULL
.	NULL

These	NULL
results	NULL
were	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
two	NULL
experiments	NULL
for	NULL
each	NULL
patient	NULL
,	NULL
and	NULL
the	NULL
assay	NULL
was	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

The	NULL
only	NULL
exception	NULL
was	NULL
patient	NULL
10129	NULL
,	NULL
for	NULL
whom	NULL
the	NULL
procedure	NULL
was	NULL
done	NULL
only	NULL
once	NULL
because	NULL
therapy	NULL
was	NULL
soon	NULL
initiated	NULL
.	NULL

AG-490-induced	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGLs	NULL
was	NULL
statistically	NULL
significant	NULL
with	NULL
P	NULL
<	NULL
0.05	NULL
by	NULL
ANOVA	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Three-color	NULL
FACS	NULL
analyses	NULL
were	NULL
performed	NULL
on	NULL
PBMCs	NULL
from	NULL
three	NULL
patients	NULL
with	NULL
LGL	NULL
leukemia	NULL
.	NULL

The	NULL
patient	NULL
's	NULL
cells	NULL
were	NULL
first	NULL
stained	NULL
with	NULL
an	NULL
isotype	NULL
control	NULL
antibody-PE	NULL
or	NULL
anti-CD8-PE	NULL
before	NULL
staining	NULL
with	NULL
annexin-V	NULL
FITC	NULL
and	NULL
7-AAD	NULL
.	NULL

A	NULL
live	NULL
gate	NULL
was	NULL
used	NULL
to	NULL
collect	NULL
either	NULL
the	NULL
CD8*	NULL
cells	NULL
or	NULL
the	NULL
CD8-	NULL
cells	NULL
,	NULL
and	NULL
then	NULL
apoptosis	NULL
was	NULL
assessed	NULL
(	NULL
c	NULL
)	NULL
.	NULL

AG-490	NULL
was	NULL
added	NULL
to	NULL
leukemic	NULL
LGLs	NULL
(	NULL
patient	NULL
10160	NULL
)	NULL
,	NULL
and	NULL
U266	NULL
cells	NULL
or	NULL
CH11	NULL
was	NULL
added	NULL
to	NULL
CEM	NULL
after	NULL
pretreatment	NULL
with	NULL
medium	NULL
(	NULL
filled	NULL
bars	NULL
)	NULL
,	NULL
or	NULL
the	NULL
caspase-3	NULL
inhibitor	NULL
Ac-DEVD-fmk	NULL
at	NULL
doses	NULL
of	NULL
25	NULL
M	NULL
(	NULL
dark	NULL
gray	NULL
bars	NULL
)	NULL
,	NULL
50	NULL
M	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
,	NULL
and	NULL
100	NULL
uM	NULL
(	NULL
light	NULL
gray	NULL
bars	NULL
)	NULL
.	NULL

The	NULL
data	NULL
are	NULL
shown	NULL
as	NULL
percent	NULL
specific	NULL
apoptosis	NULL
and	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

a	NULL
live	NULL
gate	NULL
to	NULL
collect	NULL
either	NULL
CD8+*	NULL
or	NULL
CD8-	NULL
cells	NULL
.	NULL

We	NULL
found	NULL
that	NULL
AG-490-induced	NULL
apoptosis	NULL
in	NULL
all	NULL
cells	NULL
(	NULL
iso-type	NULL
control	NULL
)	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
CD8*-enriched	NULL
leukemic	NULL
population	NULL
in	NULL
all	NULL
four	NULL
patients	NULL
examined	NULL
,	NULL
with	NULL
little	NULL
or	NULL
no	NULL
apoptosis	NULL
induced	NULL
in	NULL
the	NULL
CD8-	NULL
population	NULL
(	NULL
Figure	NULL
3b	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
only	NULL
the	NULL
leukemic	NULL
cells	NULL
,	NULL
and	NULL
not	NULL
nonleukemic	NULL
cells	NULL
,	NULL
are	NULL
sensitive	NULL
to	NULL
the	NULL
apoptosis-inducing	NULL
effects	NULL
of	NULL
AG-490	NULL
.	NULL

Cleavage	NULL
and	NULL
activation	NULL
of	NULL
caspase	NULL
proteases	NULL
actuate	NULL
the	NULL
death	NULL
machinery	NULL
involved	NULL
in	NULL
apoptosis	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

The	NULL
cell-permeable	NULL
competitive	NULL
peptide	NULL
inhibitor	NULL
Ac-DEVD-fmk	NULL
blocks	NULL
the	NULL
activity	NULL
predominantly	NULL
of	NULL
caspase-3	NULL
(	NULL
CPP32	NULL
,	NULL
YAMA	NULL
)	NULL
.	NULL

We	NULL
added	NULL
AG-490	NULL
to	NULL
leukemic	NULL
LGLs	NULL
and	NULL
U266	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
doses	NULL
of	NULL
the	NULL
caspase-3	NULL
inhibitor	NULL
.	NULL

There	NULL
was	NULL
a	NULL
dose-dependent	NULL
decrease	NULL
in	NULL
AG-490-mediated	NULL
apoptosis	NULL
in	NULL
both	NULL
U266	NULL
and	NULL
leukemic	NULL
LGLs	NULL
in	NULL
response	NULL
to	NULL
coincu-bation	NULL
with	NULL
Ac-DEVD-fmk	NULL
(	NULL
Figure	NULL
3¢	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
a	NULL
T-cell	NULL
lymphoblastic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
CEM	NULL
)	NULL
with	NULL
CH11	NULL
and	NULL
Ac-DEVD-fmk	NULL
also	NULL
resulted	NULL
in	NULL
a	NULL
considerable	NULL
decrease	NULL
in	NULL
anti-Fas-mediated	NULL
apoptosis	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
AG-490-dependent	NULL
cell	NULL
death	NULL
is	NULL
mediated	NULL
by	NULL
activation	NULL
of	NULL
caspase-3	NULL
that	NULL
is	NULL
indicative	NULL
of	NULL
apoptosis	NULL
and	NULL
not	NULL
necrosis	NULL
.	NULL

Interestingly	NULL
,	NULL
Fas-dependent	NULL
and	NULL
AG-490-dependent	NULL
apoptosis	NULL
converge	NULL
at	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
effector	NULL
caspases	NULL
.	NULL

Effects	NULL
of	NULL
AG-490	NULL
on	NULL
STAT3	NULL
DNA-binding	NULL
activity	NULL
and	NULL
expression	NULL
of	NULL
antiapoptotic	NULL
proteins	NULL
in	NULL
leukemic	NULL
LGL	NULL
s.	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
leukemic	NULL
LGLs	NULL
of	NULL
five	NULL
patients	NULL
after	NULL
incubation	NULL
for	NULL
48	NULL
hours	NULL
in	NULL
medium	NULL
containing	NULL
DMSO	NULL
or	NULL
AG-490	NULL
.	NULL

STAT-DNA	NULL
binding	NULL
activity	NULL
using	NULL
the	NULL
hSIE	NULL
probe	NULL
was	NULL
then	NULL
determined	NULL
by	NULL
EMSA	NULL
.	NULL

Leukemic	NULL
LGLs	NULL
from	NULL
all	NULL
of	NULL
these	NULL
patients	NULL
were	NULL
sensitive	NULL
to	NULL
AG-490-mediated	NULL
apoptosis	NULL
(	NULL
Figure	NULL
2a	NULL
)	NULL
.	NULL

There	NULL
was	NULL
a	NULL
decrease	NULL
in	NULL
both	NULL
STAT	NULL
3	NULL
and	NULL
STAT	NULL
1	NULL
DNA-binding	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
AG-490	NULL
treatment	NULL
in	NULL
extracts	NULL
from	NULL
all	NULL
five	NULL
patients	NULL
and	NULL
from	NULL
control	NULL
U266	NULL
cells	NULL
(	NULL
Figure	NULL
4a	NULL
)	NULL
.	NULL

oCH11	NULL
90	NULL
]	NULL
a	NULL
AG-490	NULL
sAG+CH11	NULL
x	NULL
@	NULL
cllieca	NULL
30	NULL
Specific	NULL
apoptosis	NULL
(	NULL
%	NULL
)	NULL
a	NULL
®	NULL
.A	NULL
g	NULL
wo	NULL
Normal	NULL
LGL	NULL
Leukemia	NULL
patients	NULL
b	NULL
a	NULL
Ungated	NULL
m	NULL
CD3+	NULL
o	NULL
CD8~	NULL
&	NULL
C	NULL
F	NULL
9	NULL
a.	NULL
s	NULL
]	NULL
a.	NULL
od	NULL
2	NULL
35	NULL
©	NULL
a	NULL
.	NULL

®	NULL
10128	NULL
10160	NULL
10180	NULL
10169	NULL
C	NULL
5	NULL
m	NULL
medium	NULL
a	NULL
m	NULL
25	NULL
uM	NULL
&	NULL
70	NULL
O	NULL
50	NULL
uM	NULL
3	NULL
60	NULL
©	NULL
100	NULL
uM	NULL
0	NULL
3	NULL
so	NULL
&	NULL
40	NULL
g	NULL
%	NULL
g	NULL
s	NULL
I8	NULL
20	NULL
<	NULL
9	NULL
)	NULL
“	NULL
10	NULL
0	NULL
LGL-10160	NULL
U266	NULL
+	NULL
CEM	NULL
+	NULL
+AG-490	NULL
AG-490	NULL
CH11	NULL
In	NULL
multiple-myeloma	NULL
cells	NULL
(	NULL
U266	NULL
is	NULL
an	NULL
example	NULL
)	NULL
,	NULL
an	NULL
IL-6-dependent	NULL
autocrine	NULL
or	NULL
paracrine	NULL
loop	NULL
acts	NULL
to	NULL
stimulate	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
antiapoptotic	NULL
protein	NULL
Bcl-x	NULL
;	NULL
(	NULL
9	NULL
,	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

STAT3	NULL
and	NULL
STAT	NULL
1	NULL
control	NULL
bex	NULL
transcription	NULL
(	NULL
9	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
levels	NULL
of	NULL
Bcl-2-family	NULL
antiapoptotic	NULL
proteins	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

No	NULL
Bcl-x	NULL
;	NULL
was	NULL
observed	NULL
in	NULL
leukemic	NULL
LGLs	NULL
from	NULL
six	NULL
patients	NULL
(	NULL
Figure	NULL
4b	NULL
)	NULL
.	NULL

As	NULL
described	NULL
previously	NULL
,	NULL
the	NULL
level	NULL
of	NULL
Bcl-x	NULL
;	NULL
decreased	NULL
in	NULL
AG-490-treated	NULL
U266	NULL
cells	NULL
(	NULL
Figure	NULL
4b	NULL
,	NULL
top	NULL
row	NULL
,	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
strong	NULL
relationship	NULL
between	NULL
STAT	NULL
3-mediated	NULL
Bcl-x	NULL
;	NULL
,	NULL
regulation	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
examine	NULL
further	NULL
the	NULL
role	NULL
of	NULL
Bcl-x	NULL
,	NULL
by	NULL
RNase	NULL
protection	NULL
assay	NULL
.	NULL

We	NULL
found	NULL
that	NULL
Bcl-x	NULL
,	NULL
mRNA	NULL
was	NULL
barely	NULL
detectable	NULL
in	NULL
leukemic	NULL
LGLs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Bel-2	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
was	NULL
unchanged	NULL
by	NULL
AG-490	NULL
treatment	NULL
of	NULL
leukemic	NULL
LGLs	NULL
and	NULL
U266	NULL
cells	NULL
(	NULL
Figure	NULL
4b	NULL
,	NULL
second	NULL
row	NULL
;	NULL
RNase	NULL
protection	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

AG-490	NULL
treatment	NULL
downregulates	NULL
Mcl-1	NULL
protein	NULL
expression	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
Bel-2	NULL
and	NULL
B-actin	NULL
expression	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
decrease	NULL
in	NULL
Mcl-1	NULL
protein	NULL
expression	NULL
after	NULL
AG-490	NULL
treatment	NULL
in	NULL
U266	NULL
cells	NULL
and	NULL
in	NULL
five	NULL
of	NULL
seven	NULL
samples	NULL
of	NULL
leukemic	NULL
LGLs	NULL
(	NULL
decreased	NULL
expression	NULL
was	NULL
in	NULL
the	NULL
range	NULL
of	NULL
55-98	NULL
%	NULL
after	NULL
normalization	NULL
by	NULL
densitometry	NULL
)	NULL
.	NULL

Leukemic	NULL
356	NULL
The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume107	NULL
|	NULL
Number3	NULL
LGLs	NULL
from	NULL
two	NULL
patients	NULL
demonstrated	NULL
no	NULL
reduction	NULL
in	NULL
Mcl-1	NULL
protein	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
AG-490	NULL
(	NULL
no	NULL
.	NULL

10160	NULL
,	NULL
Figure	NULL
4b	NULL
;	NULL
and	NULL
no	NULL
.	NULL

10128	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

STAT3	NULL
binds	NULL
a	NULL
promoter	NULL
element	NULL
in	NULL
the	NULL
murine	NULL
mel-1	NULL
promoter	NULL
.	NULL

Decreased	NULL
levels	NULL
of	NULL
Mcl-1	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
AG-490	NULL
suggest	NULL
that	NULL
STAT	NULL
's	NULL
may	NULL
transcriptionally	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
Mcl-1	NULL
.	NULL

An	NULL
SIE-like	NULL
binding	NULL
site	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
mouse	NULL
mel-1	NULL
promoter	NULL
and	NULL
recently	NULL
shown	NULL
to	NULL
contribute	NULL
to	NULL
IL-3-induced	NULL
mel-1	NULL
gene	NULL
expression	NULL
in	NULL
IL-3-dependent	NULL
Ba/F3	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

The	NULL
STAT	NULL
proteins	NULL
that	NULL
bound	NULL
this	NULL
element	NULL
were	NULL
not	NULL
identified	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
STAT3	NULL
could	NULL
bind	NULL
to	NULL
the	NULL
SIE	NULL
element	NULL
located	NULL
at	NULL
-103	NULL
to	NULL
-87	NULL
of	NULL
the	NULL
mel-1	NULL
promoter	NULL
,	NULL
we	NULL
performed	NULL
EMSA	NULL
assays	NULL
utilizing	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
probe	NULL
corresponding	NULL
to	NULL
this	NULL
region	NULL
and	NULL
nuclear	NULL
extracts	NULL
known	NULL
to	NULL
contain	NULL
activated	NULL
STAT	NULL
3	NULL
;	NULL
namely	NULL
,	NULL
those	NULL
from	NULL
U266	NULL
,	NULL
leukemic	NULL
LGL	NULL
s	NULL
,	NULL
and	NULL
v-src-transformed	NULL
NIH3T3	NULL
(	NULL
9	NULL
,	NULL
19	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
a	NULL
protein	NULL
complex	NULL
bound	NULL
to	NULL
this	NULL
probe	NULL
in	NULL
all	NULL
three	NULL
extracts	NULL
.	NULL

Excess	NULL
cold	NULL
oligonucleotide	NULL
competition	NULL
(	NULL
100	NULL
%	NULL
)	NULL
with	NULL
either	NULL
the	NULL
Mcl-1	NULL
SIE-DNA	NULL
or	NULL
authentic	NULL
hSIE	NULL
completely	NULL
eliminated	NULL
this	NULL
binding	NULL
activity	NULL
(	NULL
Figure	NULL
5a	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
,	NULL
8	NULL
and	NULL
9	NULL
,	NULL
and	NULL
14	NULL
and	NULL
15	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
nonspecific	NULL
FIRE	NULL
sequence	NULL
failed	NULL
to	NULL
eliminate	NULL
the	NULL
Mcl-1	NULL
SIE-DNA-binding	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
Mcl-1	NULL
SIE-DNA-binding	NULL
activity	NULL
contained	NULL
a	NULL
STAT	NULL
3	NULL
or	NULL
STAT1	NULL
protein	NULL
.	NULL

We	NULL
then	NULL
performed	NULL
supershift	NULL
analysis	NULL
with	NULL
either	NULL
anti-STAT1	NULL
or	NULL
anti-STAT3	NULL
antibodies	NULL
to	NULL
positively	NULL
identify	NULL
the	NULL
proteins	NULL
contained	NULL
within	NULL
the	NULL
DNA-binding	NULL
complex	NULL
.	NULL

In	NULL
U266	NULL
cells	NULL
,	NULL
leukemic	NULL
LGLs	NULL
,	NULL
and	NULL
v-src-transformed	NULL
NIH3T3	NULL
,	NULL
supershift	NULL
or	NULL
elimination	NULL
of	NULL
the	NULL
complex	NULL
was	NULL
observed	NULL
with	NULL
only	NULL
the	NULL
STAT	NULL
3	NULL
antibody	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
STAT3	NULL
binds	NULL
to	NULL
the	NULL
SIE-element	NULL
within	NULL
the	NULL
murine	NULL
mel-1	NULL
promoter	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
nuclear	NULL
extracts	NULL
from	NULL
p	NULL
further	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Figure	NULL
5¢c	NULL
shows	NULL
that	NULL
an	NULL
intact	NULL
SIE-binding	NULL
element	NULL
is	NULL
necessary	NULL
for	NULL
v-sre	NULL
inducibility	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
results	NULL
with	NULL
the	NULL
wild-type	NULL
mel-1	NULL
promoter	NULL
,	NULL
displayed	NULL
no	NULL
reduction	NULL
of	NULL
mel-1	NULL
basal	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
mutant	NULL
reporter	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
we	NULL
performed	NULL
experiments	NULL
with	NULL
the	NULL
pLucSRE-luciferase	NULL
identified	NULL
previously	NULL
as	NULL
v-src-inducible	NULL
by	NULL
a	NULL
STAT3-independent	NULL
mechanism	NULL
.	NULL

As	NULL
demonstrated	NULL
previously	NULL
,	NULL
the	NULL
pLucSRE	NULL
was	NULL
inducible	NULL
by	NULL
v-src	NULL
overexpression	NULL
,	NULL
but	NULL
no	NULL
inhibition	NULL
was	NULL
observed	NULL
by	NULL
coexpression	NULL
of	NULL
STAT	NULL
3B	NULL
(	NULL
28	NULL
)	NULL
.	NULL

We	NULL
concluded	NULL
from	NULL
these	NULL
data	NULL
that	NULL
the	NULL
mel-1	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
STAT	NULL
3	NULL
element	NULL
in	NULL
the	NULL
murine	NULL
mel-1	NULL
promoter	NULL
and	NULL
that	NULL
STAT	NULL
overexpression	NULL
does	NULL
not	NULL
interfere	NULL
non-specifically	NULL
with	NULL
v-src-induced	NULL
promoter	NULL
activity	NULL
.	NULL

Endogenous	NULL
levels	NULL
of	NULL
Mcl-1	NULL
protein	NULL
induced	NULL
by	NULL
v-src	NULL
overex-pression	NULL
.	NULL

The	NULL
inducibility	NULL
of	NULL
Mcl-1	NULL
protein	NULL
by	NULL
v-src	NULL
was	NULL
examined	NULL
in	NULL
NIH3T3	NULL
without	NULL
and	NULL
with	NULL
v-src	NULL
overex-pression	NULL
.	NULL

In	NULL
comparison	NULL
to	NULL
STAT	NULL
3	NULL
and	NULL
B-actin	NULL
,	NULL
Mcl-1	NULL
expression	NULL
was	NULL
enhanced	NULL
by	NULL
v-src	NULL
(	NULL
Figure	NULL
5d	NULL
)	NULL
.	NULL

These	NULL
data	NULL
corroborate	NULL
the	NULL
results	NULL
observed	NULL
with	NULL
in	NULL
vitro	NULL
reporter	NULL
assays	NULL
using	NULL
the	NULL
mel-1	NULL
-luciferase	NULL
construct	NULL
.	NULL

Kinetic	NULL
analysis	NULL
of	NULL
AG-490	NULL
treatment	NULL
.	NULL

Kinetic	NULL
analysis	NULL
was	NULL
performed	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
reduction	NULL
in	NULL
Mcl-1	NULL
protein	NULL
expression	NULL
and	NULL
STAT3	NULL
activity	NULL
preceded	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
induced	NULL
by	NULL
AG-490	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
Mcl-1	NULL
,	NULL
Bel-2	NULL
,	NULL
and	NULL
B-actin	NULL
in	NULL
DMSO	NULL
and	NULL
AG-490-treated	NULL
leukemic	NULL
LGLs	NULL
was	NULL
performed	NULL
on	NULL
extracts	NULL
collected	NULL
after	NULL
6	NULL
,	NULL
12	NULL
,	NULL
24	NULL
,	NULL
and	NULL
36	NULL
hours	NULL
'	NULL
incubation	NULL
.	NULL

At	NULL
each	NULL
time	NULL
point	NULL
,	NULL
cells	NULL
were	NULL
also	NULL
studied	NULL
for	NULL
apoptosis	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
only	NULL
after	NULL
12	NULL
and	NULL
24	NULL
hours	NULL
owing	NULL
to	NULL
the	NULL
limited	NULL
number	NULL
of	NULL
cells	NULL
avail	NULL
hSIE	NULL
Probe	NULL
10137	NULL
10160	NULL
10013	NULL
10093	NULL
10129	NULL
U266	NULL
3	NULL
GO	NULL
3	NULL
O	NULL
3	NULL
O	NULL
3	NULL
O	NULL
3	NULL
O	NULL
3	NULL
O	NULL
Treatments	NULL
:	NULL
Q	NULL
<	NULL
o	NULL
<	NULL
o	NULL
<	NULL
o	NULL
<	NULL
o	NULL
<	NULL
o	NULL
<	NULL
leukemic	NULL
LGL	NULL
consistently	NULL
bound	NULL
the	NULL
Mcl-1	NULL
SIE	NULL
element	NULL
,	NULL
we	NULL
performed	NULL
EMSA	NULL
assays	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
DMSO	NULL
and	NULL
AG-490-treated	NULL
-	NULL
leukemic	NULL
-	NULL
LGL	NULL
.	NULL

-	NULL
Mcl-1-SIE-DNA-binding	NULL
activity	NULL
was	NULL
present	NULL
in	NULL
all	NULL
extracts	NULL
examined	NULL
and	NULL
was	NULL
significantly	NULL
reduced	NULL
by	NULL
AG-490	NULL
treatment	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
.	NULL

Mcl-1	NULL
gene	NULL
regulation	NULL
is	NULL
induced	NULL
by	NULL
v-src	NULL
expression	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
murine	NULL
mel-1	NULL
gene	NULL
is	NULL
transcriptionally	NULL
activated	NULL
by	NULL
STAT3	NULL
,	NULL
a	NULL
tran-scriptional-reporter	NULL
assay	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
murine	NULL
mel-1	NULL
promoter	NULL
fused	NULL
to	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
by	NULL
transient	NULL
transfection	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

(	NULL
28	NULL
,	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
mel-1	NULL
promoter	NULL
was	NULL
induced	NULL
by	NULL
coexpression	NULL
of	NULL
v-src	NULL
in	NULL
NIH3T	NULL
3	NULL
(	NULL
Figure	NULL
5¢	NULL
)	NULL
.	NULL

Inducible	NULL
expression	NULL
was	NULL
completely	NULL
abolished	NULL
by	NULL
cotransfection	NULL
of	NULL
a	NULL
dominant-negative	NULL
pSGS5-STAT3	NULL
(	NULL
STAT3PB	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
induction	NULL
of	NULL
the	NULL
mel-1	NULL
promoter	NULL
by	NULL
v-src	NULL
is	NULL
STAT	NULL
3-dependent	NULL
.	NULL

Control	NULL
experiments	NULL
with	NULL
the	NULL
pSG5	NULL
empty	NULL
vector	NULL
displayed	NULL
no	NULL
inhibition	NULL
of	NULL
reporter	NULL
activity	NULL
.	NULL

An	NULL
mel-1	NULL
promoter	NULL
construct	NULL
harboring	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
SIE-binding	NULL
element	NULL
was	NULL
used	NULL
to	NULL
confirm	NULL
these	NULL
results	NULL
<	NULL
®	NULL
'	NULL
@	NULL
its	NULL
®	NULL
l	NULL
#	NULL
:	NULL
:	NULL
=ST11	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
_	NULL
ro	NULL
to	NULL
B	NULL
b	NULL
101374	NULL
10160	NULL
100134	NULL
100934	NULL
10129	NULL
``	NULL
10203	NULL
``	NULL
U266A	NULL
=	NULL
O	NULL
=	NULL
0	NULL
3	NULL
0	NULL
=	NULL
0	NULL
o	NULL
<	NULL
o	NULL
<	NULL
o	NULL
<	NULL
oA	NULL
<	NULL
mime	NULL
-	NULL
anti-Bcl-x	NULL
,	NULL
UD	NULL
«	NULL
w	NULL
Hb	NULL
-	NULL
-..	NULL
m	NULL
cam	NULL
Wipes	NULL
»	NULL
anti-Bci-2	NULL
*_*	NULL
agp	NULL
B	NULL
am	NULL
UID	NULL
aap	NULL
«	NULL
we	NULL
--	NULL
--	NULL
B®	NULL
«	NULL
»	NULL
anti-	NULL
Mci-1	NULL
«	NULL
_	NULL
<	NULL
p	NULL
gp	NULL
uP	NULL
car	NULL
G4	NULL
GP	NULL
GB	NULL
Cpe	NULL
»	NULL
me	NULL
egg	NULL
o-	NULL
co-1	NULL
-	NULL
20	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
WB	NULL
Figure	NULL
4	NULL
AG-490-reduced	NULL
DNA-binding	NULL
activity	NULL
of	NULL
STAT3	NULL
and	NULL
expression	NULL
of	NULL
Mcl-1	NULL
.	NULL

(	NULL
a	NULL
)	NULL
EMSA	NULL
with	NULL
leukemic	NULL
LGLs	NULL
(	NULL
lanes	NULL
1-10	NULL
)	NULL
or	NULL
U266	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
treated	NULL
with	NULL
DMSO	NULL
(	NULL
DM	NULL
;	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
11	NULL
)	NULL
or	NULL
AG-490	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
position	NULL
of	NULL
STAT3:3	NULL
homodimers	NULL
(	NULL
ST3:3	NULL
)	NULL
,	NULL
STAT1:3	NULL
heterodimers	NULL
(	NULL
ST1:3	NULL
)	NULL
,	NULL
and	NULL
STAT1:1	NULL
homodimers	NULL
(	NULL
ST1:1	NULL
)	NULL
is	NULL
indicated	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
for	NULL
five	NULL
patients	NULL
with	NULL
LGL	NULL
leukemia	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

A	NULL
statistically	NULL
significant	NULL
decrease	NULL
in	NULL
EMSA	NULL
binding	NULL
occurred	NULL
in	NULL
all	NULL
AG-490-treated	NULL
cells	NULL
tested	NULL
compared	NULL
with	NULL
DMSO	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
using	NULL
Student	NULL
's	NULL
t	NULL
test	NULL
.	NULL
)	NULL

(	NULL
b	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
for	NULL
expression	NULL
of	NULL
Bel-x	NULL
,	NULL
,	NULL
Bel-2	NULL
,	NULL
Mcl-1	NULL
,	NULL
and	NULL
B-actin	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
total	NULL
protein	NULL
was	NULL
used	NULL
for	NULL
U266	NULL
cells	NULL
and	NULL
25	NULL
pug	NULL
for	NULL
leukemic	NULL
LGLs	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
on	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
gel	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

AStatistically	NULL
significant	NULL
decrease	NULL
in	NULL
Mcl-1	NULL
expression	NULL
after	NULL
AG-490	NULL
treatment	NULL
;	NULL
P	NULL
<	NULL
0.05	NULL
using	NULL
Student	NULL
's	NULL
¢	NULL
test	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
February	NULL
2001	NULL
|	NULL
Volume107	NULL
|	NULL
Number3	NULL
357	NULL
3000000	NULL
28000004	NULL
26000004	NULL
24000004	NULL
220000047	NULL
20000004	NULL
18000004	NULL
16000004	NULL
14000004	NULL
12000004	NULL
10000004	NULL
8000004	NULL
6000004	NULL
4000004	NULL
2000004	NULL
Ill	NULL
0	NULL
mel-1	NULL
v-src	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
=	NULL
*+	NULL
=	NULL
+	NULL
pSGS5	NULL
empty	NULL
vector	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
=	NULL
-	NULL
+	NULL
=	NULL
pSG5	NULL
hSTAT3B	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
=	NULL
=-	NULL
-	NULL
#	NULL
d	NULL
Mcl-1	NULL
SIE	NULL
Probe	NULL
anti-ST1	NULL
anti-ST3	NULL
anti-ST1	NULL
anti-ST3	NULL
anti-ST3	NULL
EMSA	NULL
ST3	NULL
:	NULL
.3	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
Normalized	NULL
arbitrary	NULL
luciferase	NULL
unit	NULL
ﬁ	NULL
pLucSRE	NULL
luciferase	NULL
constructs	NULL
:	NULL
mel-	NULL
1mSlE	NULL
-	NULL
bo-	NULL
4	NULL
0	NULL
-	NULL
4+	NULL
4	NULL
«	NULL
ok	NULL
$	NULL
pok	NULL
s	NULL
-	NULL
#	NULL
mom	NULL
om	NULL
wp	NULL
ok	NULL
k	NULL
om	NULL
g	NULL
Mcl-1	NULL
SIE	NULL
Probe	NULL
10013	NULL
=	NULL
O	NULL
o	NULL
<	NULL
6	NULL
10137	NULL
=	NULL
G0	NULL
o	NULL
<	NULL
10160	NULL
=	NULL
0	NULL
o	NULL
<	NULL
10093	NULL
=	NULL
0	NULL
o	NULL
<	NULL
o	NULL
¥	NULL
=	NULL
8	NULL
9	NULL
7	NULL
U266	NULL
=	NULL
O	NULL
<	NULL
I	NULL
EMSA	NULL
V-SrCl	NULL
.	NULL

-	NULL
_+	NULL
ST3:3	NULL
«	NULL
-	NULL
3	NULL
``	NULL
anti-Mcl-1	NULL
f	NULL
g	NULL
semper	NULL
anti-ST3	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
seeps	NULL
»	NULL
anti-B-actin	NULL
10	NULL
2	NULL
10	NULL
Figure	NULL
5	NULL
STAT3	NULL
DNA-binding	NULL
to	NULL
an	NULL
SIE-like	NULL
element	NULL
in	NULL
the	NULL
Mcl-1	NULL
promoter	NULL
and	NULL
transcription	NULL
regulation	NULL
.	NULL

(	NULL
a	NULL
)	NULL
EMSA	NULL
was	NULL
performed	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
U266	NULL
(	NULL
lanes	NULL
1-6	NULL
)	NULL
,	NULL
leukemic	NULL
LGLs	NULL
(	NULL
patient	NULL
10169	NULL
;	NULL
lanes	NULL
7-12	NULL
)	NULL
,	NULL
and	NULL
vsrc-transformed	NULL
NIH3T3	NULL
(	NULL
lanes	NULL
13-17	NULL
)	NULL
with	NULL
the	NULL
Mcl-1	NULL
SIE	NULL
probe	NULL
labeled	NULL
with	NULL
P2	NULL
.	NULL

Competition	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
adding	NULL
excess	NULL
cold	NULL
oligonucleotide	NULL
(	NULL
x100	NULL
)	NULL
for	NULL
McISIE	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
8	NULL
,	NULL
and	NULL
14	NULL
)	NULL
,	NULL
hSIE	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
9	NULL
,	NULL
and	NULL
15	NULL
)	NULL
,	NULL
and	NULL
nonspecific	NULL
competitor	NULL
(	NULL
FIRE	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
10	NULL
,	NULL
and	NULL
16	NULL
)	NULL
.	NULL

Blocking	NULL
or	NULL
supershift	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
adding	NULL
anti-STAT1	NULL
antibody	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
11	NULL
)	NULL
or	NULL
anti-STAT3	NULL
antibody	NULL
(	NULL
lanes	NULL
6	NULL
,	NULL
12	NULL
,	NULL
and	NULL
17	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

(	NULL
b	NULL
)	NULL
EMSA	NULL
analysis	NULL
with	NULL
me/-1	NULL
SIE	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
leukemic	NULL
LGLs	NULL
(	NULL
lanes	NULL
1-8	NULL
)	NULL
or	NULL
U266	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
treated	NULL
with	NULL
solvent	NULL
control	NULL
(	NULL
DMSO	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
)	NULL
or	NULL
AG-490	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
experiments	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Transcriptional	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
transfection	NULL
of	NULL
NIH3T3	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
pGL2	NULL
mel-1	NULL
(	NULL
p-203/+10mel-luc	NULL
)	NULL
,	NULL
pGL2	NULL
mSIE	NULL
mel-1	NULL
(	NULL
p-203/+10m5S	NULL
)	NULL
,	NULL
and	NULL
pLucSRE-luciferase	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
4	NULL
ug	NULL
vsre	NULL
,	NULL
pSGS-STAT3B	NULL
,	NULL
and	NULL
pSGS	NULL
vector	NULL
control	NULL
expression	NULL
vectors	NULL
.	NULL

The	NULL
values	NULL
shown	NULL
are	NULL
normalized	NULL
by	NULL
cotransfection	NULL
with	NULL
CMV-B-galactosidase	NULL
expression	NULL
vectors	NULL
.	NULL

(	NULL
d	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
in	NULL
NIH3T3	NULL
without	NULL
(	NULL
-	NULL
)	NULL
or	NULL
with	NULL
(	NULL
+	NULL
)	NULL
vsre	NULL
overexpression	NULL
for	NULL
Mcl-1	NULL
,	NULL
STAT3	NULL
,	NULL
and	NULL
B-actin	NULL
protein	NULL
expression	NULL
.	NULL

358	NULL
able	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
Mcl-1	NULL
in	NULL
relation	NULL
to	NULL
B-actin	NULL
had	NULL
decreased	NULL
in	NULL
AG-490-treated	NULL
cells	NULL
by	NULL
12	NULL
hours	NULL
(	NULL
Figure	NULL
6a	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
reduction	NULL
in	NULL
STAT	NULL
3	NULL
activation	NULL
by	NULL
EMSA	NULL
analysis	NULL
was	NULL
also	NULL
apparent	NULL
after	NULL
12	NULL
hours	NULL
(	NULL
Figure	NULL
6c	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
drug-induced	NULL
apoptosis	NULL
was	NULL
not	NULL
induced	NULL
until	NULL
24	NULL
hours	NULL
(	NULL
Figure	NULL
6b	NULL
)	NULL
.	NULL

There	NULL
was	NULL
a	NULL
rapid	NULL
AG-490-mediated	NULL
decline	NULL
in	NULL
Mcl-1	NULL
protein	NULL
expression	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

Rapid	NULL
degradation	NULL
of	NULL
Mcl-1	NULL
has	NULL
been	NULL
previously	NULL
linked	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
PEST	NULL
sequence	NULL
in	NULL
the	NULL
protein	NULL
(	NULL
34	NULL
)	NULL
.	NULL

These	NULL
data	NULL
are	NULL
suggestive	NULL
but	NULL
not	NULL
conclusive	NULL
for	NULL
a	NULL
role	NULL
of	NULL
Mcl-1	NULL
in	NULL
AG-490-mediated	NULL
apoptosis	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

Antisense	NULL
STAT3	NULL
reverses	NULL
Fas	NULL
resistance	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
possibility	NULL
that	NULL
AG-490	NULL
impacts	NULL
multiple	NULL
signaling	NULL
pathways	NULL
mediated	NULL
by	NULL
JAK-tyrosine	NULL
kinases	NULL
,	NULL
we	NULL
used	NULL
an	NULL
antisense	NULL
approach	NULL
to	NULL
reduce	NULL
STAT	NULL
3	NULL
levels	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Figure	NULL
7a	NULL
demonstrates	NULL
that	NULL
extracts	NULL
obtained	NULL
from	NULL
leukemic	NULL
LGLs	NULL
treated	NULL
with	NULL
antisense	NULL
STAT3	NULL
(	NULL
AS-ST3	NULL
)	NULL
contained	NULL
lower	NULL
levels	NULL
of	NULL
STAT3	NULL
protein	NULL
in	NULL
comparison	NULL
with	NULL
cells	NULL
incubated	NULL
with	NULL
medium	NULL
and	NULL
control	NULL
oligonucleotide	NULL
.	NULL

These	NULL
results	NULL
were	NULL
reproducible	NULL
in	NULL
experiments	NULL
using	NULL
leukemic	NULL
LGLs	NULL
from	NULL
each	NULL
of	NULL
three	NULL
patients	NULL
,	NULL
with	NULL
the	NULL
percent	NULL
of	NULL
reduction	NULL
in	NULL
STAT	NULL
3	NULL
protein	NULL
in	NULL
the	NULL
range	NULL
of	NULL
25-45	NULL
%	NULL
.	NULL

Sensitivity	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
was	NULL
significantly	NULL
increased	NULL
in	NULL
the	NULL
AS-STAT3-treated	NULL
cells	NULL
(	NULL
Fig-	NULL
ure	NULL
7b	NULL
)	NULL
,	NULL
an	NULL
effect	NULL
that	NULL
was	NULL
dose	NULL
dependent	NULL
(	NULL
Figure	NULL
7¢c	NULL
)	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
Mcl-1	NULL
protein	NULL
expression	NULL
was	NULL
decreased	NULL
in	NULL
response	NULL
to	NULL
AS-STAT3	NULL
(	NULL
Figure	NULL
7d	NULL
)	NULL
,	NULL
supporting	NULL
a	NULL
direct	NULL
role	NULL
for	NULL
STAT3	NULL
in	NULL
Mcl-1	NULL
signaling	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
antisense	NULL
for	NULL
STAT	NULL
3	NULL
,	NULL
STAT1	NULL
protein	NULL
levels	NULL
were	NULL
also	NULL
determined	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
STAT3	NULL
reduction	NULL
,	NULL
there	NULL
was	NULL
no	NULL
effect	NULL
of	NULL
oligonucleotide	NULL
treatment	NULL
on	NULL
STAT1	NULL
expression	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
a	NULL
and	NULL
d	NULL
)	NULL
.	NULL

Discussion	NULL
Here	NULL
we	NULL
report	NULL
that	NULL
leukemic	NULL
LGL	NULL
from	NULL
all	NULL
19	NULL
patients	NULL
tested	NULL
constitutively	NULL
expressed	NULL
high	NULL
levels	NULL
of	NULL
activated	NULL
STAT3	NULL
and/or	NULL
STAT	NULL
1	NULL
.	NULL

Unlike	NULL
normal	NULL
TCR-stimulated	NULL
T	NULL
cells	NULL
,	NULL
STATS	NULL
was	NULL
distinctly	NULL
absent	NULL
in	NULL
leukemic	NULL
LGLs	NULL
from	NULL
all	NULL
but	NULL
two	NULL
patients	NULL
examined	NULL
(	NULL
36	NULL
,	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

IL-2	NULL
is	NULL
not	NULL
expressed	NULL
constitutively	NULL
or	NULL
after	NULL
anti-CD3	NULL
stimulation	NULL
in	NULL
leukemic	NULL
LGLs	NULL
(	NULL
8	NULL
,	NULL
45-47	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
leukemic	NULL
cells	NULL
do	NULL
express	NULL
the	NULL
intermediate	NULL
affinity	NULL
IL-2	NULL
receptor	NULL
containing	NULL
the	NULL
B	NULL
and	NULL
y	NULL
subunits	NULL
and	NULL
become	NULL
sensitive	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
after	NULL
treatment	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
IL-2	NULL
in	NULL
vitro	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
signaling	NULL
pathway	NULL
mediated	NULL
by	NULL
IL-2	NULL
is	NULL
intact	NULL
(	NULL
45-47	NULL
)	NULL
.	NULL

IL-2-deficient	NULL
mice	NULL
share	NULL
some	NULL
features	NULL
in	NULL
common	NULL
with	NULL
LGL	NULL
leukemia	NULL
,	NULL
such	NULL
as	NULL
splenomegaly	NULL
and	NULL
autoantibody	NULL
formation	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Also	NULL
similar	NULL
to	NULL
LGL	NULL
The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume	NULL
107	NULL
|_	NULL
Number	NULL
3	NULL
R	NULL
0	NULL
12	NULL
h_	NULL
AG-490	NULL
:	NULL
1	NULL
``	NULL
.-ST3	NULL
:	NULL
13	NULL
24h	NULL
.	NULL

o	NULL
o	NULL
w	NULL
o	NULL
o	NULL
ho	NULL
co	NULL
1	NULL
B+/2	NULL
to	NULL
0	NULL
a	NULL
_o	NULL
in	NULL
AG-490-treated	NULL
cells	NULL
a	NULL
o	NULL
6	NULL
12	NULL
24	NULL
36	NULL
Duration	NULL
of	NULL
treatment	NULL
(	NULL
h	NULL
)	NULL
~	NULL
%	NULL
Reduction	NULL
in	NULL
Mcl-1	NULL
expression	NULL
{	NULL
J	NULL
30	NULL
25	NULL
20	NULL
Specific	NULL
apoptosis	NULL
(	NULL
%	NULL
)	NULL
a	NULL
Duration	NULL
of	NULL
treatment	NULL
(	NULL
h	NULL
)	NULL
Figure	NULL
6	NULL
Kinetic	NULL
analysis	NULL
with	NULL
AG-490	NULL
treatment	NULL
.	NULL

Leukemic	NULL
LGLs	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
or	NULL
AG-490	NULL
for	NULL
6	NULL
,	NULL
12	NULL
,	NULL
24	NULL
,	NULL
and	NULL
36	NULL
hours	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Graphic	NULL
representation	NULL
of	NULL
the	NULL
percent	NULL
reduction	NULL
in	NULL
Mcl-1	NULL
expression	NULL
in	NULL
AG-490-treated	NULL
cells	NULL
in	NULL
comparison	NULL
with	NULL
DMSO-treated	NULL
cells	NULL
.	NULL

Mcl-1	NULL
protein	NULL
expression	NULL
was	NULL
normalized	NULL
to	NULL
B-actin	NULL
by	NULL
densitometry	NULL
using	NULL
the	NULL
ImageQuant	NULL
program	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Degree	NULL
of	NULL
annex-in-V-FITC-positive	NULL
binding	NULL
with	NULL
percent	NULL
specific	NULL
apoptosis	NULL
,	NULL
calculated	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
,	NULL
in	NULL
leukemic	NULL
LGLs	NULL
treated	NULL
for	NULL
12	NULL
,	NULL
18	NULL
,	NULL
24	NULL
,	NULL
36	NULL
,	NULL
and	NULL
42	NULL
hours	NULL
in	NULL
DMSO	NULL
and	NULL
AG-490	NULL
.	NULL

(	NULL
c	NULL
)	NULL
EMSA	NULL
for	NULL
STAT3	NULL
activity	NULL
with	NULL
DMSO-treated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
AG-490-treated	NULL
(	NULL
+	NULL
)	NULL
cells	NULL
after	NULL
12	NULL
and	NULL
24	NULL
hours	NULL
.	NULL

Data	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
results	NULL
in	NULL
two	NULL
patients	NULL
.	NULL

The	NULL
apoptosis	NULL
assay	NULL
was	NULL
performed	NULL
in	NULL
duplicate	NULL
in	NULL
each	NULL
patient	NULL
.	NULL

leukemia	NULL
,	NULL
the	NULL
IL-2/-	NULL
cells	NULL
are	NULL
phenotypically	NULL
characteristic	NULL
of	NULL
antigen	NULL
activated	NULL
T	NULL
cells	NULL
but	NULL
are	NULL
resistant	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
despite	NULL
expression	NULL
of	NULL
Fas	NULL
(	NULL
43	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
IL-2	NULL
production	NULL
and	NULL
the	NULL
absence	NULL
of	NULL
STAT	NULL
5	NULL
activation	NULL
may	NULL
prove	NULL
to	NULL
be	NULL
an	NULL
important	NULL
factor	NULL
in	NULL
the	NULL
growth	NULL
and	NULL
survival	NULL
of	NULL
leukemic	NULL
LGLs	NULL
.	NULL

We	NULL
hypothesized	NULL
that	NULL
the	NULL
dysregulated	NULL
STAT	NULL
activation	NULL
was	NULL
involved	NULL
in	NULL
cell	NULL
survival	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
used	NULL
a	NULL
tyrphostin	NULL
inhibitor	NULL
(	NULL
AG-490	NULL
)	NULL
selective	NULL
for	NULL
the	NULL
JAK-family	NULL
tyrosine	NULL
kinases	NULL
to	NULL
determine	NULL
whether	NULL
inhibition	NULL
of	NULL
the	NULL
pathway	NULL
upstream	NULL
of	NULL
STAT	NULL
activation	NULL
would	NULL
affect	NULL
apoptosis	NULL
in	NULL
LGL	NULL
leukemia	NULL
cells	NULL
(	NULL
32	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
PBMCs	NULL
from	NULL
these	NULL
patients	NULL
underwent	NULL
apoptosis	NULL
in	NULL
response	NULL
to	NULL
AG-490	NULL
treatment	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
STAT	NULL
pathway	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
cell	NULL
survival	NULL
.	NULL

However	NULL
,	NULL
reversal	NULL
of	NULL
the	NULL
Fas-resistant	NULL
phenotype	NULL
was	NULL
observed	NULL
in	NULL
leukemic	NULL
LGLs	NULL
from	NULL
only	NULL
two	NULL
of	NULL
ten	NULL
patients	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
biochemical	NULL
differences	NULL
exist	NULL
in	NULL
the	NULL
mechanism	NULL
for	NULL
cell	NULL
survival	NULL
and	NULL
Fas	NULL
resistance	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

Prote-olytic	NULL
cleavage	NULL
and	NULL
activation	NULL
of	NULL
a	NULL
cascade	NULL
of	NULL
caspases	NULL
(	NULL
death	NULL
proteases	NULL
)	NULL
mediate	NULL
the	NULL
cleavage	NULL
of	NULL
cellular	NULL
tar-gets	NULL
,	NULL
resulting	NULL
in	NULL
programmed	NULL
cell	NULL
death	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

To	NULL
ascertain	NULL
the	NULL
role	NULL
of	NULL
the	NULL
effector	NULL
caspases	NULL
in	NULL
AG-490-mediated	NULL
apoptosis	NULL
,	NULL
we	NULL
performed	NULL
experiments	NULL
with	NULL
the	NULL
inhibitor	NULL
Ac-DEVD-fmk	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
caspase	NULL
inhibitor	NULL
blocked	NULL
AG-490-induced	NULL
apoptosis	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
,	NULL
in	NULL
both	NULL
leukemic	NULL
LGLs	NULL
and	NULL
U266	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
CH11-treated	NULL
CEMs	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
AG-490-induced	NULL
death	NULL
results	NULL
from	NULL
apoptosis	NULL
rather	NULL
than	NULL
nonspecific	NULL
activation	NULL
of	NULL
necrosis	NULL
and	NULL
that	NULL
AG-490	NULL
and	NULL
Fas-mediated	NULL
cell	NULL
death	NULL
converge	NULL
at	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
effector	NULL
caspases	NULL
.	NULL

The	NULL
signaling	NULL
pathway	NULL
resulting	NULL
in	NULL
STAT	NULL
3	NULL
activation	NULL
in	NULL
leukemic	NULL
LGLs	NULL
is	NULL
not	NULL
known	NULL
.	NULL

In	NULL
myeloma	NULL
,	NULL
STAT	NULL
activation	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
an	NULL
IL-6	NULL
feedback	NULL
loop	NULL
.	NULL

Possible	NULL
mechanisms	NULL
in	NULL
leukemic	NULL
LGLs	NULL
could	NULL
include	NULL
the	NULL
following	NULL
:	NULL
(	NULL
a	NULL
)	NULL
a	NULL
survival-promoting	NULL
autocrine	NULL
or	NULL
paracrine	NULL
cytokine	NULL
pathway	NULL
;	NULL
(	NULL
b	NULL
)	NULL
dysregulated	NULL
STAT	NULL
activation	NULL
due	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
production	NULL
;	NULL
and	NULL
(	NULL
c	NULL
)	NULL
activation	NULL
by	NULL
retroviral	NULL
infection	NULL
.	NULL

The	NULL
sera	NULL
of	NULL
approxi-	NULL
35	NULL
a	NULL
s	NULL
,	NULL
b	NULL
_	NULL
3	NULL
<	NULL
&	NULL
*	NULL
2	NULL
__	NULL
ﬂ	NULL
.P	NULL
25	NULL
E	NULL
E	NULL
<	NULL
(	NULL
Z	NULL
Z	NULL
|-	NULL
a	NULL
0	NULL
O	NULL
~	NULL
&	NULL
~	NULL
meee	NULL
seme	NULL
sos	NULL
anti-ST3	NULL
a.	NULL
.	NULL

®	NULL
15	NULL
mem-	NULL
e	NULL
anti-	NULL
ST	NULL
1	NULL
o	NULL
waue	NULL
amie	NULL
ames	NULL
anti-Bax	NULL
“	NULL
5	NULL
10	NULL
seme	NULL
»	NULL
sume	NULL
»	NULL
smmes	NULL
ANti-B-ACtIN	NULL
l	NULL
5	NULL
10	NULL
2003	NULL
to	NULL
cNTL	NULL
|	NULL
as-sts|	NULL
cHi1	NULL
+	NULL
]	NULL
CH11+	NULL
Oligo	NULL
CNTL	NULL
_	NULL
AS-ST3	NULL
Oligo	NULL
Oligo	NULL
Treatment	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
c	NULL
30	NULL
d	NULL
_	NULL
,	NULL
o	NULL
Con+CH11	NULL
|U_3	NULL
251	NULL
-	NULL
mas-ST3HCH11	NULL
5	NULL
u	NULL
O	NULL
_	NULL
<	NULL
20	NULL
wee	NULL
<	NULL
anti-ST3	NULL
spate	NULL
anti-Mcl-1	NULL
seee	NULL
==	NULL
anti-S	NULL
T	NULL
1	NULL
seems	NULL
anti-B-actin	NULL
Specific	NULL
apoptosis	NULL
(	NULL
%	NULL
)	NULL
5	NULL
a	NULL
&	NULL
n	NULL
0	NULL
1	NULL
2	NULL
5	NULL
Dose	NULL
of	NULL
Oligonucleotide	NULL
(	NULL
uM	NULL
)	NULL
Figure	NULL
7	NULL
Sensitivity	NULL
to	NULL
Fas	NULL
and	NULL
reduced	NULL
expression	NULL
of	NULL
Mcl-1	NULL
in	NULL
leukemic	NULL
LGLs	NULL
treated	NULL
with	NULL
antisense	NULL
STAT3	NULL
.	NULL

Leukemic	NULL
LGLs	NULL
(	NULL
patient	NULL
10160	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
medium	NULL
(	NULL
CNTL	NULL
)	NULL
,	NULL
1	NULL
M	NULL
control	NULL
oligonucleotide	NULL
(	NULL
CNTL	NULL
oligo	NULL
)	NULL
,	NULL
or	NULL
1	NULL
LM	NULL
antisense	NULL
STAT3	NULL
oligonucleotide	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
for	NULL
STAT3	NULL
,	NULL
STAT1	NULL
,	NULL
Bax	NULL
,	NULL
and	NULL
B-actin	NULL
expression	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Annexin-V-FITC	NULL
binding	NULL
was	NULL
determined	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
CH11+	NULL
)	NULL
or	NULL
absence	NULL
of	NULL
agonistic	NULL
anti-Fas	NULL
antibody	NULL
.	NULL

Data	NULL
shown	NULL
are	NULL
calculations	NULL
of	NULL
percent	NULL
specific	NULL
apoptosis	NULL
of	NULL
the	NULL
average	NULL
results	NULL
obtained	NULL
in	NULL
duplicate	NULL
reactions	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Specific	NULL
apoptosis	NULL
calculated	NULL
for	NULL
control	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
antisense	NULL
STAT3	NULL
oligonucleotide	NULL
(	NULL
filled	NULL
bars	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
0	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
5	NULL
M	NULL
oligonucleotides	NULL
(	NULL
patient	NULL
10205	NULL
)	NULL
.	NULL

(	NULL
d	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
LM	NULL
control	NULL
oligonucleotide	NULL
(	NULL
Con	NULL
)	NULL
or	NULL
antisense	NULL
STAT	NULL
3	NULL
oligonucleotide	NULL
(	NULL
AS-ST3	NULL
)	NULL
for	NULL
expression	NULL
of	NULL
STAT3	NULL
,	NULL
Mel-1	NULL
,	NULL
STAT1	NULL
,	NULL
and	NULL
B-actin	NULL
protein	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume	NULL
107	NULL
|	NULL
Number	NULL
3	NULL
359	NULL
360	NULL
mately	NULL
50	NULL
%	NULL
of	NULL
LGL	NULL
leukemia	NULL
patients	NULL
are	NULL
reactive	NULL
to	NULL
an	NULL
HTLV	NULL
envelope	NULL
protein	NULL
,	NULL
suggesting	NULL
infection	NULL
with	NULL
an	NULL
HTLV-related	NULL
virus	NULL
(	NULL
48	NULL
,	NULL
49	NULL
)	NULL
.	NULL

STAT3	NULL
was	NULL
found	NULL
to	NULL
positively	NULL
regulate	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
antiapoptotic	NULL
protein	NULL
and	NULL
control	NULL
the	NULL
IL-6-dependent	NULL
survival	NULL
of	NULL
U266	NULL
cells	NULL
(	NULL
9	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
failed	NULL
to	NULL
detect	NULL
Bcl-x	NULL
;	NULL
protein	NULL
in	NULL
leukemic	NULL
LGL	NULL
.	NULL

Our	NULL
data	NULL
suggested	NULL
that	NULL
a	NULL
Bel-xr-inde-pendent	NULL
pathway	NULL
was	NULL
involved	NULL
in	NULL
the	NULL
AG-490-induced	NULL
cell	NULL
death	NULL
observed	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

We	NULL
then	NULL
evaluated	NULL
other	NULL
members	NULL
of	NULL
the	NULL
Bcl-2-family	NULL
proteins	NULL
as	NULL
possible	NULL
candidates	NULL
.	NULL

The	NULL
mel-1	NULL
gene	NULL
was	NULL
recently	NULL
demonstrated	NULL
to	NULL
be	NULL
controlled	NULL
by	NULL
both	NULL
PI3-K-mediated	NULL
CRE-2	NULL
activation	NULL
and	NULL
PI3-K-independ-ent	NULL
activation	NULL
of	NULL
an	NULL
SIE	NULL
(	NULL
STAT3-like	NULL
)	NULL
sequence	NULL
in	NULL
response	NULL
to	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

It	NULL
was	NULL
also	NULL
shown	NULL
that	NULL
elevation	NULL
in	NULL
Mcl-1	NULL
protein	NULL
expression	NULL
correlated	NULL
with	NULL
relapse	NULL
in	NULL
acute	NULL
leukemias	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Mcl-1	NULL
,	NULL
when	NULL
overexpressed	NULL
,	NULL
can	NULL
inhibit	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
multiple	NULL
apoptotic	NULL
stimuli	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
cell	NULL
survival	NULL
(	NULL
51-53	NULL
)	NULL
.	NULL

We	NULL
carefully	NULL
examined	NULL
whether	NULL
STAT	NULL
3	NULL
was	NULL
capable	NULL
of	NULL
transcriptionally	NULL
regulating	NULL
the	NULL
murine	NULL
mel-1	NULL
promoter	NULL
in	NULL
v-src-transformed	NULL
NIH3T3	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
the	NULL
SIE-like	NULL
element	NULL
in	NULL
the	NULL
mel-1	NULL
promoter	NULL
was	NULL
STAT3	NULL
responsive	NULL
and	NULL
v-src	NULL
inducibility	NULL
was	NULL
dependent	NULL
on	NULL
this	NULL
site	NULL
.	NULL

A	NULL
correlation	NULL
between	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
mel-1	NULL
promoter	NULL
can	NULL
not	NULL
be	NULL
made	NULL
at	NULL
this	NULL
time	NULL
because	NULL
the	NULL
human	NULL
genomic	NULL
sequence	NULL
for	NULL
mcl-1	NULL
is	NULL
yet	NULL
to	NULL
be	NULL
cloned	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
Mcl-1	NULL
antiapoptotic	NULL
activity	NULL
has	NULL
not	NULL
been	NULL
established	NULL
,	NULL
but	NULL
the	NULL
protein	NULL
binds	NULL
to	NULL
proapoptotic	NULL
Bcel-2-family	NULL
members	NULL
Bax-0	NULL
,	NULL
hypophosphorylated	NULL
BAD	NULL
,	NULL
Bak	NULL
,	NULL
Bok	NULL
,	NULL
Bik	NULL
,	NULL
and	NULL
BOD	NULL
(	NULL
54-56	NULL
)	NULL
.	NULL

The	NULL
ratio	NULL
of	NULL
anti-	NULL
and	NULL
proapoptotic	NULL
proteins	NULL
determines	NULL
cell	NULL
survival	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
reduction	NULL
in	NULL
Mcl-1	NULL
protein	NULL
by	NULL
inhibition	NULL
of	NULL
STAT	NULL
signaling	NULL
may	NULL
contribute	NULL
to	NULL
apoptotic	NULL
induction	NULL
in	NULL
leukemic	NULL
LGLs	NULL
.	NULL

Further	NULL
experiments	NULL
are	NULL
needed	NULL
to	NULL
define	NULL
more	NULL
clearly	NULL
the	NULL
role	NULL
of	NULL
Mcl-1	NULL
in	NULL
abnormal	NULL
cell	NULL
survival	NULL
.	NULL

Because	NULL
Mcl-1	NULL
has	NULL
antiapoptotic	NULL
activity	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
Mcl-1	NULL
gene	NULL
expression	NULL
by	NULL
oncogenic	NULL
v-src-induced	NULL
STAT	NULL
3	NULL
has	NULL
potentially	NULL
important	NULL
implications	NULL
in	NULL
mechanisms	NULL
of	NULL
tumorigenesis	NULL
.	NULL

These	NULL
studies	NULL
provide	NULL
an	NULL
important	NULL
demonstration	NULL
that	NULL
an	NULL
AG-490-inhibitable	NULL
pathway	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
survival	NULL
of	NULL
primary	NULL
tumor	NULL
cells	NULL
such	NULL
as	NULL
leukemia	NULL
samples	NULL
as	NULL
well	NULL
as	NULL
malignant	NULL
cell	NULL
lines	NULL
.	NULL

Cell	NULL
survival	NULL
by	NULL
the	NULL
JAK/STAT	NULL
pathway	NULL
appears	NULL
complex	NULL
,	NULL
involving	NULL
control	NULL
of	NULL
antiapoptotic	NULL
proteins	NULL
and	NULL
possibly	NULL
other	NULL
unidentified	NULL
mechanisms	NULL
.	NULL

Recent	NULL
data	NULL
has	NULL
demonstrated	NULL
that	NULL
AG-490	NULL
inhibits	NULL
not	NULL
only	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
but	NULL
also	NULL
mitogen-activated-protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
,	NULL
another	NULL
well-known	NULL
pathway	NULL
involved	NULL
in	NULL
cell	NULL
survival	NULL
and	NULL
proliferation	NULL
(	NULL
57	NULL
)	NULL
.	NULL

In	NULL
leukemic	NULL
LGLs	NULL
,	NULL
enhanced	NULL
apoptosis	NULL
after	NULL
anti-Fas	NULL
ligation	NULL
was	NULL
observed	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
antisense	NULL
STAT	NULL
3	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
STAT	NULL
3	NULL
activation	NULL
contributes	NULL
to	NULL
Fas	NULL
resistance	NULL
and	NULL
implicate	NULL
this	NULL
signaling	NULL
pathway	NULL
in	NULL
abnormal	NULL
survival	NULL
of	NULL
leukemic	NULL
LGL	NULL
.	NULL

Results	NULL
of	NULL
these	NULL
studies	NULL
identify	NULL
the	NULL
STAT3	NULL
signaling	NULL
pathway	NULL
as	NULL
molecular	NULL
targets	NULL
for	NULL
drug	NULL
discovery	NULL
in	NULL
LGL	NULL
leukemia	NULL
and	NULL
possibly	NULL
other	NULL
chronic	NULL
lymphoproliferative	NULL
diseases	NULL
(	NULL
58	NULL
)	NULL
.	NULL

Acknowledgments	NULL
This	NULL
investigation	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Veterans	NULL
Administration	NULL
,	NULL
an	NULL
institutional	NULL
research	NULL
grant	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
(	NULL
1093-02	NULL
)	NULL
,	NULL
and	NULL
grants	NULL
awarded	NULL
by	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
(	NULL
CA-78724	NULL
and	NULL
CA-55652	NULL
)	NULL
.	NULL

We	NULL
thank	NULL
William	NULL
Dalton	NULL
and	NULL
Terry	NULL
Landowski	NULL
for	NULL
their	NULL
informative	NULL
suggestion	NULL
on	NULL
the	NULL
manuscript	NULL
preparation	NULL
and	NULL
data	NULL
analysis	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
the	NULL
Flow	NULL
Cytometry	NULL
Core	NULL
Facility	NULL
at	NULL
Moffitt	NULL
Cancer	NULL
Center	NULL
for	NULL
acquisition	NULL
and	NULL
analysis	NULL
of	NULL
flow	NULL
cytometry	NULL
data	NULL
,	NULL
and	NULL
Alan	NULL
Cantor	NULL
of	NULL
the	NULL
Biostatistics	NULL
Core	NULL
for	NULL
statistical	NULL
analysis	NULL
.	NULL

1	NULL
.	NULL

Loughran	NULL
,	NULL
TP	NULL
.	NULL

,	NULL
Jr.	NULL
1993	NULL
.	NULL

Clonal	NULL
diseases	NULL
of	NULL
large	NULL
granular	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
.	NULL

82:1-14	NULL
.	NULL

2	NULL
.	NULL

Semenzato	NULL
,	NULL
G.	NULL
,	NULL
Zambello	NULL
,	NULL
R.	NULL
,	NULL
Starkebaum	NULL
,	NULL
G.	NULL
,	NULL
Oshimi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Loughran	NULL
,	NULL
T.P	NULL
.	NULL

,	NULL
Jr.	NULL
1997	NULL
.	NULL

The	NULL
lymphoproliferative	NULL
disease	NULL
of	NULL
granular	NULL
lymphocytes	NULL
:	NULL
updated	NULL
criteria	NULL
for	NULL
diagnosis	NULL
.	NULL

Blood	NULL
.	NULL

89:256-260	NULL
.	NULL

3	NULL
.	NULL

Oshimi	NULL
,	NULL
K.	NULL
,	NULL
Shinkai	NULL
,	NULL
Y.	NULL
,	NULL
Okumura	NULL
,	NULL
K.	NULL
,	NULL
Oshimi	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Mizoguchi	NULL
,	NULL
H.	NULL
1990	NULL
.	NULL

Perforin	NULL
gene	NULL
expression	NULL
in	NULL
granular	NULL
lymphocyte	NULL
proliferative	NULL
dis-orders	NULL
.	NULL

Blood	NULL
.	NULL

75:704-708	NULL
.	NULL

4	NULL
.	NULL

Van	NULL
Parijs	NULL
,	NULL
L.	NULL
,	NULL
Ibraghimov	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Abbas	NULL
,	NULL
A.K	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
roles	NULL
of	NULL
cos-timulation	NULL
and	NULL
Fas	NULL
in	NULL
T	NULL
cell	NULL
apoptosis	NULL
and	NULL
peripheral	NULL
tolerance	NULL
.	NULL

Imm	NULL
«	NULL
-nity	NULL
.	NULL

4321-328	NULL
.	NULL

5	NULL
.	NULL

Spaner	NULL
,	NULL
D.	NULL
,	NULL
Raju	NULL
,	NULL
K.	NULL
,	NULL
Radvanyi	NULL
,	NULL
L.	NULL
,	NULL
Lin	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Miller	NULL
,	NULL
R.J.	NULL
1998	NULL
.	NULL

A	NULL
role	NULL
for	NULL
perforin	NULL
in	NULL
activation-induced	NULL
cell	NULL
death	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:2655-2664	NULL
.	NULL

6	NULL
.	NULL

Watanabe-Fukunaga	NULL
,	NULL
R.	NULL
,	NULL
Brannan	NULL
,	NULL
CL	NULL
,	NULL
Copeland	NULL
,	NULL
N.G	NULL
.	NULL

,	NULL
Jenkins	NULL
,	NULL
N.A	NULL
.	NULL

,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
1992	NULL
.	NULL

Lymphoproliferative	NULL
disorder	NULL
in	NULL
mice	NULL
explained	NULL
by	NULL
defects	NULL
in	NULL
Fas	NULL
antigen	NULL
that	NULL
mediates	NULL
apoptosis	NULL
.	NULL

Nature	NULL
.	NULL

356:314-317	NULL
.	NULL

7	NULL
.	NULL

Takahashi	NULL
,	NULL
T.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Generalized	NULL
Iymphoproliferative	NULL
disease	NULL
in	NULL
mice	NULL
,	NULL
caused	NULL
by	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
Fas	NULL
ligand	NULL
.	NULL

Cell	NULL
.	NULL

76:969-976	NULL
.	NULL

8	NULL
.	NULL

Lamy	NULL
,	NULL
T.	NULL
,	NULL
Liu	NULL
,	NULL
J.H	NULL
.	NULL

,	NULL
Landowski	NULL
,	NULL
T.H	NULL
.	NULL

,	NULL
Dalton	NULL
,	NULL
W.S	NULL
.	NULL

,	NULL
and	NULL
Loughran	NULL
,	NULL
T.P	NULL
.	NULL

,	NULL
Jr.	NULL
1998	NULL
.	NULL

Dysregulation	NULL
of	NULL
CD95/CD95	NULL
ligand-apoptotic	NULL
pathway	NULL
in	NULL
CD3+	NULL
large	NULL
granular	NULL
lymphocyte	NULL
leukemia	NULL
.	NULL

Blood	NULL
.	NULL

92:4771-4777	NULL
.	NULL

9	NULL
.	NULL

Catlett-Falcone	NULL
,	NULL
R.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
Stat3	NULL
signaling	NULL
confers	NULL
resistance	NULL
to	NULL
apoptosis	NULL
in	NULL
human	NULL
myeloma	NULL
tumor	NULL
cells	NULL
.	NULL

Immunity	NULL
.	NULL

10:105-115	NULL
.	NULL

10	NULL
.	NULL

Wagner	NULL
,	NULL
BJ	NULL
.	NULL

,	NULL
Hayes	NULL
,	NULL
T.E	NULL
.	NULL

,	NULL
Hoban	NULL
,	NULL
CJ	NULL
.	NULL

,	NULL
and	NULL
Cochran	NULL
,	NULL
B.H	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
SIF	NULL
binding	NULL
element	NULL
confers	NULL
sis/PDGF	NULL
inducibility	NULL
onto	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:4477-4484	NULL
.	NULL

11	NULL
.	NULL

Seidel	NULL
,	NULL
HM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Spacing	NULL
of	NULL
palindromic	NULL
half	NULL
sites	NULL
as	NULL
a	NULL
determinant	NULL
of	NULL
selective	NULL
STAT	NULL
(	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcrip-tion	NULL
)	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

92:3041-3045	NULL
.	NULL

12	NULL
.	NULL

Milocco	NULL
,	NULL
LH	NULL
.	NULL

,	NULL
Haslam	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Rosen	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Seidel	NULL
,	NULL
H.M.	NULL
1999	NULL
.	NULL

Design	NULL
of	NULL
conditionally	NULL
active	NULL
STAT	NULL
's	NULL
:	NULL
insights	NULL
into	NULL
STAT	NULL
activation	NULL
and	NULL
gene	NULL
regulatory	NULL
function	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

19:2913-2920	NULL
.	NULL

13	NULL
.	NULL

Frank	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Robertson	NULL
,	NULL
M.J.	NULL
,	NULL
Bonni	NULL
,	NULL
A.	NULL
,	NULL
Ritz	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Greenberg	NULL
,	NULL
M.E	NULL
.	NULL

1995	NULL
.	NULL

Interleukin	NULL
2	NULL
signaling	NULL
involves	NULL
the	NULL
phosphorylation	NULL
of	NULL
Stat	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

92:7779-7783	NULL
.	NULL

14	NULL
.	NULL

Greenlund	NULL
,	NULL
A.C.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Stat	NULL
recruitment	NULL
by	NULL
tyrosine-phosphory-lated	NULL
cytokine	NULL
receptors	NULL
:	NULL
an	NULL
ordered	NULL
reversible	NULL
affinity-driven	NULL
process	NULL
.	NULL

Immunity	NULL
.	NULL

2:677-687	NULL
.	NULL

15	NULL
.	NULL

Liu	NULL
,	NULL
KD	NULL
.	NULL

,	NULL
Gaffen	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
and	NULL
Goldsmith	NULL
,	NULL
M.A	NULL
.	NULL

1998	NULL
.	NULL

JAK/STAT	NULL
signaling	NULL
by	NULL
cytokine	NULL
receptors	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

10:271-278	NULL
.	NULL

16	NULL
.	NULL

Heinrich	NULL
,	NULL
P.C	NULL
.	NULL

,	NULL
Behrmann	NULL
,	NULL
I.	NULL
,	NULL
Muller-Newen	NULL
,	NULL
G.	NULL
,	NULL
Schaper	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Graeve	NULL
,	NULL
L.	NULL
1998	NULL
.	NULL

Interleukin-6-type	NULL
cytokine	NULL
signalling	NULL
through	NULL
the	NULL
gp130/Jak/STAT	NULL
pathway	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

334:297-314	NULL
.	NULL

17	NULL
.	NULL

Mayajima	NULL
,	NULL
A.	NULL
,	NULL
Ito	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Kinoshita	NULL
,	NULL
T.	NULL
1999	NULL
.	NULL

Cytokine	NULL
signaling	NULL
for	NULL
pro-liferation	NULL
,	NULL
survival	NULL
,	NULL
and	NULL
death	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Hematol	NULL
.	NULL

69:137-146	NULL
.	NULL

18	NULL
.	NULL

Garcia	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Jove	NULL
,	NULL
R.	NULL
1998	NULL
.	NULL

Activation	NULL
of	NULL
STAT	NULL
transcription	NULL
factors	NULL
in	NULL
oncogenic	NULL
tyrosine	NULL
kinase	NULL
signaling	NULL
.	NULL

J.	NULL
Biomed	NULL
.	NULL

Sci	NULL
.	NULL

5:79-85	NULL
.	NULL

19	NULL
.	NULL

Yu	NULL
,	NULL
C.-L.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Enhanced	NULL
DNA-binding	NULL
activity	NULL
of	NULL
a	NULL
Stat3-related	NULL
protein	NULL
in	NULL
cells	NULL
transformed	NULL
by	NULL
the	NULL
Src	NULL
oncoprotein	NULL
.	NULL

Science	NULL
.	NULL

269:81-83	NULL
.	NULL

20	NULL
.	NULL

Danial	NULL
,	NULL
N.N	NULL
.	NULL

,	NULL
Pernis	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Rothman	NULL
,	NULL
P.B	NULL
.	NULL

1995	NULL
.	NULL

Jak-STAT	NULL
signaling	NULL
induced	NULL
by	NULL
the	NULL
v-abl	NULL
oncogene	NULL
.	NULL

Science	NULL
.	NULL

269:1875-1877	NULL
.	NULL

21	NULL
.	NULL

Nelson	NULL
,	NULL
KL	NULL
.	NULL

,	NULL
Rogers	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Bowman	NULL
,	NULL
T.L	NULL
.	NULL

,	NULL
Jove	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Smithgall	NULL
,	NULL
T.E	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
STAT3	NULL
by	NULL
the	NULL
c-Fes	NULL
protein-tyrosine	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:7072-7077	NULL
.	NULL

22	NULL
.	NULL

Besser	NULL
,	NULL
D.	NULL
,	NULL
Bromberg	NULL
,	NULL
E.J	NULL
.	NULL

,	NULL
Darnell	NULL
,	NULL
J.E.J	NULL
.	NULL

,	NULL
and	NULL
Hanafusa	NULL
,	NULL
H.	NULL
1999	NULL
.	NULL

A	NULL
single	NULL
amino	NULL
acid	NULL
substitution	NULL
in	NULL
the	NULL
v-Eyk	NULL
intracellular	NULL
domain	NULL
results	NULL
in	NULL
The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume	NULL
107	NULL
|_	NULL
Number	NULL
3	NULL
activation	NULL
of	NULL
Stat3	NULL
and	NULL
enhances	NULL
cellular	NULL
transformation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

19:1401-1409	NULL
.	NULL

23	NULL
.	NULL

Garcia	NULL
,	NULL
R.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
Stat3	NULL
in	NULL
fibroblasts	NULL
transformed	NULL
by	NULL
diverse	NULL
oncoproteins	NULL
and	NULL
in	NULL
breast	NULL
carcinoma	NULL
cells	NULL
.	NULL

Cell	NULL
.	NULL

Growth	NULL
Diff	NULL
.	NULL

8:1267-1276	NULL
.	NULL

24	NULL
.	NULL

Gouilleux-Gruart	NULL
,	NULL
V.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

STAT-related	NULL
transcription	NULL
factors	NULL
are	NULL
constitutively	NULL
activated	NULL
in	NULL
peripheral	NULL
blood	NULL
cells	NULL
from	NULL
acute	NULL
leukemia	NULL
patients	NULL
.	NULL

Blood	NULL
.	NULL

87:1692-1697	NULL
.	NULL

25	NULL
.	NULL

Chai	NULL
,	NULL
S.K	NULL
.	NULL

,	NULL
Nichols	NULL
,	NULL
G.L	NULL
.	NULL

,	NULL
and	NULL
Rothman	NULL
,	NULL
P.	NULL
1997	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
JAKs	NULL
and	NULL
STAT	NULL
's	NULL
in	NULL
BCR-Abl-expressing	NULL
cell	NULL
lines	NULL
and	NULL
peripheral	NULL
blood	NULL
cells	NULL
derived	NULL
from	NULL
leukemic	NULL
patients	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:4720-4728	NULL
.	NULL

26	NULL
.	NULL

Grundis	NULL
,	NULL
J.R.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Requirement	NULL
of	NULL
Stat3	NULL
but	NULL
not	NULL
Stat1	NULL
activation	NULL
for	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptor-mediated	NULL
cell	NULL
growth	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

102:1385-1392	NULL
.	NULL

27	NULL
.	NULL

Sun	NULL
,	NULL
W.HL	NULL
.	NULL

,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Interferon-alpha	NULL
resistance	NULL
in	NULL
a	NULL
cutaneous	NULL
T-cell	NULL
lymphoma	NULL
cell	NULL
line	NULL
is	NULL
associated	NULL
with	NULL
lack	NULL
of	NULL
STAT1	NULL
expression	NULL
.	NULL

Blood	NULL
.	NULL

91:570-576	NULL
.	NULL

28	NULL
.	NULL

Turkson	NULL
,	NULL
J.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Stat3	NULL
activation	NULL
by	NULL
Src	NULL
induces	NULL
specific	NULL
gene	NULL
regulation	NULL
and	NULL
is	NULL
required	NULL
for	NULL
cell	NULL
transformation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:2545-2552	NULL
.	NULL

29	NULL
.	NULL

Bromberg	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

Stat3	NULL
as	NULL
an	NULL
oncogene	NULL
.	NULL

Cell	NULL
.	NULL

98:295-303	NULL
.	NULL

30	NULL
.	NULL

Bromberg	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
Horvath	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
Besser	NULL
,	NULL
D.	NULL
,	NULL
Lathem	NULL
,	NULL
W.W.	NULL
,	NULL
and	NULL
Darnell	NULL
,	NULL
J.E.J	NULL
.	NULL

1998	NULL
.	NULL

Stat3	NULL
activation	NULL
is	NULL
required	NULL
for	NULL
cellular	NULL
transformation	NULL
by	NULL
v-src	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:2553-2558	NULL
.	NULL

31	NULL
.	NULL

Wakao	NULL
,	NULL
H.	NULL
,	NULL
Gouilleux	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Groner	NULL
,	NULL
B	NULL
.	NULL

1995	NULL
.	NULL

Mammary	NULL
gland	NULL
factor	NULL
(	NULL
MGF	NULL
)	NULL
is	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
cytokine	NULL
regulated	NULL
transcription	NULL
factor	NULL
gene	NULL
family	NULL
and	NULL
confers	NULL
the	NULL
prolactin	NULL
response	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:854-855	NULL
.	NULL

32	NULL
.	NULL

Meydan	NULL
,	NULL
N.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Inhibition	NULL
of	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
by	NULL
a	NULL
Jak-2	NULL
inhibitor	NULL
.	NULL

Nature	NULL
.	NULL

379:645-648	NULL
.	NULL

33	NULL
.	NULL

Karras	NULL
,	NULL
J.G	NULL
.	NULL

,	NULL
et	NULL
al	NULL
.	NULL

2000	NULL
.	NULL

STAT3	NULL
regulates	NULL
the	NULL
growth	NULL
and	NULL
immunoglob-ulin	NULL
production	NULL
of	NULL
BCL	NULL
(	NULL
1	NULL
)	NULL
B	NULL
cell	NULL
lymphoma	NULL
through	NULL
control	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

202:124-135	NULL
.	NULL

34	NULL
.	NULL

Chao	NULL
,	NULL
J.-R.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998.	NULL
mel-1	NULL
is	NULL
an	NULL
immediate-early	NULL
gene	NULL
activated	NULL
by	NULL
the	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
signaling	NULL
pathway	NULL
and	NULL
is	NULL
a	NULL
component	NULL
of	NULL
the	NULL
GM-CSF	NULL
viability	NULL
response	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:4883-4898	NULL
.	NULL

35	NULL
.	NULL

Wang	NULL
,	NULL
J.-M.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
antiapoptotic	NULL
gene	NULL
mel-1	NULL
is	NULL
up-regulated	NULL
by	NULL
the	NULL
phosphatidylinositol	NULL
3-kinase/Akt	NULL
signaling	NULL
pathway	NULL
through	NULL
a	NULL
transcription	NULL
factor	NULL
complex	NULL
containing	NULL
CREB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
19:6195-6206	NULL
.	NULL

36	NULL
.	NULL

Lin	NULL
,	NULL
J.X	NULL
.	NULL

,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
role	NULL
of	NULL
shared	NULL
receptor	NULL
motifs	NULL
and	NULL
common	NULL
Stat	NULL
proteins	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
cytokine	NULL
pleiotropy	NULL
and	NULL
redundancy	NULL
by	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
IL-7	NULL
,	NULL
IL-13	NULL
,	NULL
and	NULL
IL-15	NULL
.	NULL

Immunity	NULL
.	NULL

4:331-339	NULL
.	NULL

37	NULL
.	NULL

Welte	NULL
,	NULL
T.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

STATS	NULL
interaction	NULL
with	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
complex	NULL
and	NULL
stimulation	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

Science	NULL
.	NULL

8:222-225	NULL
.	NULL

38	NULL
.	NULL

Enari	NULL
,	NULL
M.	NULL
,	NULL
Hug	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
1995	NULL
.	NULL

Involvement	NULL
of	NULL
an	NULL
ICE-like	NULL
protease	NULL
in	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Nature	NULL
.	NULL

375:78-81	NULL
.	NULL

39	NULL
.	NULL

Nicholson	NULL
,	NULL
D.W.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Identification	NULL
and	NULL
inhibition	NULL
of	NULL
the	NULL
ICE/CED-3	NULL
protease	NULL
necessary	NULL
for	NULL
mammalian	NULL
apoptosis	NULL
.	NULL

Nature	NULL
.	NULL

376:37-43	NULL
.	NULL

40	NULL
.	NULL

Ferlin-Bezombes	NULL
,	NULL
M.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

IFN-alpha	NULL
is	NULL
a	NULL
survival	NULL
factor	NULL
for	NULL
human	NULL
myeloma	NULL
cells	NULL
and	NULL
reduces	NULL
dexamethasone-induced	NULL
apoptosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:2692-2699	NULL
.	NULL

41	NULL
.	NULL

Treon	NULL
,	NULL
S.P	NULL
.	NULL

,	NULL
and	NULL
Anderson	NULL
,	NULL
K.C	NULL
.	NULL

1998	NULL
.	NULL

Interleukin-6	NULL
in	NULL
multiple	NULL
myeloma	NULL
and	NULL
related	NULL
plasma	NULL
cell	NULL
dyscrasias	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Hematol	NULL
.	NULL

5:42-48	NULL
.	NULL

42	NULL
.	NULL

Fujio	NULL
,	NULL
Y.	NULL
,	NULL
Kunisada	NULL
,	NULL
K.	NULL
,	NULL
Hirota	NULL
,	NULL
H.	NULL
,	NULL
Yamauchi-Takihara	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Kishi-moto	NULL
,	NULL
T.	NULL
1997	NULL
.	NULL

Signals	NULL
through	NULL
gp130	NULL
upregulate	NULL
bel-x	NULL
gene	NULL
expression	NULL
via	NULL
STAT1-binding	NULL
ciselement	NULL
in	NULL
cardiac	NULL
myocytes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

99:2898-2905	NULL
.	NULL

43	NULL
.	NULL

Berridge	NULL
,	NULL
M.J.	NULL
1997	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
in	NULL
health	NULL
and	NULL
disease	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

17:155-178	NULL
.	NULL

44	NULL
.	NULL

Kneitz	NULL
,	NULL
B.	NULL
,	NULL
Herrman	NULL
,	NULL
T.	NULL
,	NULL
Yonehara	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Schimpl	NULL
,	NULL
A	NULL
.	NULL

1995	NULL
.	NULL

Normal	NULL
clonal	NULL
expansion	NULL
but	NULL
impaired	NULL
Fas-mediated	NULL
cell	NULL
death	NULL
and	NULL
anergy	NULL
induction	NULL
in	NULL
interleukin-2-deficient	NULL
mice	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:2572-2577	NULL
.	NULL

45	NULL
.	NULL

Loughran	NULL
,	NULL
TP	NULL
.	NULL

,	NULL
Jr.	NULL
,	NULL
Aprile	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
and	NULL
Ruscetti	NULL
,	NULL
F.W	NULL
.	NULL

1990	NULL
.	NULL

Anti-CD3	NULL
mon-oclonal	NULL
antibody-mediated	NULL
cytotoxicity	NULL
occurs	NULL
through	NULL
an	NULL
interleukin-2-independent	NULL
pathway	NULL
in	NULL
CD3+	NULL
large	NULL
granular	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
.	NULL

4:935-940	NULL
.	NULL

46	NULL
.	NULL

Yoon	NULL
,	NULL
HJ	NULL
.	NULL

,	NULL
Sugamura	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Loughran	NULL
,	NULL
T.P	NULL
.	NULL

,	NULL
Jr.	NULL
1990	NULL
.	NULL

Activation	NULL
of	NULL
leukemic	NULL
large	NULL
granular	NULL
lymphocytes	NULL
by	NULL
interleukin-2	NULL
via	NULL
the	NULL
p75	NULL
interleukin-2	NULL
receptor	NULL
.	NULL

Leakemia	NULL
.	NULL

4:848-850	NULL
.	NULL

47	NULL
.	NULL

Zambello	NULL
,	NULL
R.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1990	NULL
.	NULL

Cell	NULL
membrane	NULL
expression	NULL
and	NULL
functional	NULL
role	NULL
of	NULL
the	NULL
p75	NULL
subunit	NULL
of	NULL
interleukin-2	NULL
receptor	NULL
in	NULL
lymphoproliferative	NULL
disease	NULL
of	NULL
granular	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
.	NULL

76:2080-2085	NULL
.	NULL

48	NULL
.	NULL

Loughran	NULL
,	NULL
TP	NULL
.	NULL

,	NULL
Jr.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Epitope	NULL
mapping	NULL
of	NULL
HTLV	NULL
envelope	NULL
seroreactivity	NULL
in	NULL
LGL	NULL
leukaemia	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

101:318-324	NULL
.	NULL

49	NULL
.	NULL

Loughran	NULL
,	NULL
T.P	NULL
.	NULL

1996	NULL
.	NULL

HTLV	NULL
infection	NULL
and	NULL
hematologic	NULL
malignancies	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

20:457-458	NULL
.	NULL

50	NULL
.	NULL

Kaufmann	NULL
,	NULL
SH	NULL
.	NULL

,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Elevated	NULL
expression	NULL
of	NULL
the	NULL
apoptotic	NULL
regulator	NULL
Mcl-1	NULL
at	NULL
the	NULL
time	NULL
of	NULL
leukemic	NULL
relapse	NULL
.	NULL

Blood	NULL
.	NULL

91:991-1000	NULL
.	NULL

51	NULL
.	NULL

Kozopas	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Yang	NULL
,	NULL
T.	NULL
,	NULL
Buchan	NULL
,	NULL
HL	NULL
.	NULL

,	NULL
Zhou	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Craig	NULL
,	NULL
RW	NULL
.	NULL

1993	NULL
.	NULL

Mcl-1	NULL
,	NULL
a	NULL
gene	NULL
expressed	NULL
in	NULL
programmed	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
has	NULL
sequence	NULL
similarity	NULL
to	NULL
Bcl2	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

90:3516-3520	NULL
.	NULL

52	NULL
.	NULL

Reynolds	NULL
,	NULL
J.E	NULL
.	NULL

,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Mcl-1	NULL
a	NULL
member	NULL
of	NULL
the	NULL
Bcl-2	NULL
family	NULL
,	NULL
delays	NULL
apoptosis	NULL
induced	NULL
by	NULL
c-Myc	NULL
overexpression	NULL
in	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:6348-6352	NULL
.	NULL

53	NULL
.	NULL

Zhou	NULL
,	NULL
P.	NULL
,	NULL
Quian	NULL
,	NULL
L.	NULL
,	NULL
Kozopas	NULL
,	NULL
KM	NULL
.	NULL

,	NULL
and	NULL
Craig	NULL
,	NULL
RW	NULL
.	NULL

1997	NULL
.	NULL

Mcl-1	NULL
,	NULL
a	NULL
bel-2	NULL
family	NULL
member	NULL
,	NULL
delays	NULL
the	NULL
death	NULL
of	NULL
hematopoietic	NULL
cells	NULL
under	NULL
a	NULL
variety	NULL
of	NULL
apoptosis-inducing	NULL
conditions	NULL
.	NULL

Blood	NULL
.	NULL

89:630-643	NULL
.	NULL

54	NULL
.	NULL

Wang	NULL
,	NULL
K.	NULL
,	NULL
Gross	NULL
,	NULL
A.	NULL
,	NULL
Waksman	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Korsmeyer	NULL
,	NULL
S.J	NULL
.	NULL

1998	NULL
.	NULL

Mutagene-sis	NULL
of	NULL
the	NULL
BH3	NULL
domain	NULL
of	NULL
BAX	NULL
identifies	NULL
residues	NULL
critical	NULL
for	NULL
dimerization	NULL
and	NULL
killing	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:6083-6089	NULL
.	NULL

55	NULL
.	NULL

Hsu	NULL
,	NULL
S.Y	NULL
.	NULL

,	NULL
Lin	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Hsueh	NULL
,	NULL
A.J	NULL
.	NULL

1998	NULL
.	NULL

BOD	NULL
(	NULL
Bcl-2-related	NULL
ovarian	NULL
death	NULL
gene	NULL
)	NULL
is	NULL
an	NULL
ovarian	NULL
BH3	NULL
domain-containing	NULL
proapoptotic	NULL
Bcl-2	NULL
protein	NULL
capable	NULL
of	NULL
dimerization	NULL
with	NULL
diverse	NULL
antiapoptotic	NULL
Bcl-2	NULL
members	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

12:1432-1440	NULL
.	NULL

56	NULL
.	NULL

Hsu	NULL
,	NULL
S.Y	NULL
.	NULL

,	NULL
Kaipia	NULL
,	NULL
A.	NULL
,	NULL
McGee	NULL
,	NULL
E.	NULL
,	NULL
Lomeli	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hsueh	NULL
,	NULL
AJ	NULL
.	NULL

1997	NULL
.	NULL

Bok	NULL
is	NULL
a	NULL
pro-apoptotic	NULL
Bel-2	NULL
protein	NULL
with	NULL
restricted	NULL
expression	NULL
in	NULL
reproductive	NULL
tissues	NULL
and	NULL
heterodimerizes	NULL
with	NULL
selective	NULL
anti-apoptotic	NULL
Bcl-2	NULL
family	NULL
members	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

94:12401-12406	NULL
.	NULL

57	NULL
.	NULL

Wang	NULL
,	NULL
LH	NULL
.	NULL

,	NULL
Kirken	NULL
,	NULL
R.A.	NULL
,	NULL
Erwin	NULL
,	NULL
RA	NULL
.	NULL

,	NULL
Yu	NULL
,	NULL
C.R	NULL
.	NULL

,	NULL
and	NULL
Farrar	NULL
,	NULL
W.L	NULL
.	NULL

1999	NULL
.	NULL

JAK3	NULL
,	NULL
STAT	NULL
,	NULL
and	NULL
MAPK	NULL
signaling	NULL
pathways	NULL
as	NULL
novel	NULL
molecular	NULL
targets	NULL
for	NULL
the	NULL
tyrphostin	NULL
AG-490	NULL
regulation	NULL
of	NULL
IL-2-mediated	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:3897-3904	NULL
.	NULL

58	NULL
.	NULL

Levitzki	NULL
,	NULL
A	NULL
.	NULL

1999	NULL
.	NULL

Protein	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
as	NULL
novel	NULL
therapeutic	NULL
agents	NULL
.	NULL

Pharmacol	NULL
.	NULL

Ther	NULL
.	NULL

82:231-239	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
|	NULL
February	NULL
2001	NULL
|	NULL
Volume107	NULL
|	NULL
Number3	NULL
361	NULL

